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 1. BACKGROUND 
 
1.1. Introduction and summary of the background  
 
General issues  
This thesis concerns several aspects of urinary incontinence after radical prostatectomy (RP) 
for prostate cancer (PCa), such as identification of prevalence and predictors of urinary 
leakage, results of urodynamic examinations, and outcomes of surgical treatment for 
persistent urinary leakage. 
Currently an increasing number of Norwegian men are diagnosed with PCa every year, 
close to 5,000 new cases in Norway in 2012 1. For patients with clinically localized PCa, RP 
and radiation therapy (RT) are offered as curative treatment options, with similar oncologic 
outcomes. Each treatment modality is followed by a typical pattern of adverse effects (AEs). 
Following RP, erectile dysfunction and urinary leakage are the most frequent AEs. Following 
RT, urinary irritation, sexual and bowel dysfunctions are common 2. There is a wide disparity 
in the reported prevalence rates of these AEs, probably due to different definitions, evaluation 
methods, and patient samples 3,4. 
Before treatment the responsible doctor counsels patients as to eventual oncologic and 
functional outcomes. The counselling is given on an individual basis according to treatment 
modality considered and preoperative risk factors present. A crucial aspect of realistic 
preoperative counselling is that relevant information is available. Hence local and national 
studies of treatment outcomes are of considerable importance. Based on such outcomes, 
counselling and rational choices of treatment can be made by the patients. Thereby long-term 
satisfaction may be achieved within the perspective of having been optimally treated for PCa, 
accepting the risk of unavoidable AEs. 
 
Postprostatectomy incontinence (PPI) 
Reported PPI rates range from 2% to 74%, depending on the definition applied. Potential risk 
factors for PPI include higher age, preoperative incontinence, comorbidity, and PCa 
characteristics (clinical stage, clinical PCa risk group, etc.), as well as peroperative technical 
factors (nerve sparing, apical dissection, bladder neck preservation, surgeon’s experience) 3.  
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 Wide anatomic dissection around the prostate during RP can damage the nerve and 
blood supply of the bladder, bladder neck, sphincter, and urethra, with resulting insufficiency 
of the continence mechanism and possibly damage to the bladder muscle 5.  
PPI can be due to urethral sphincter dysfunction, causing stress incontinence, or 
bladder dysfunction, causing urgency incontinence, or both (mixed incontinence). The 
pathophysiology of PPI can be characterized by urodynamic studies, and treatment options 
for PPI can be selected accordingly. However, surgical treatment of sphincter dysfunction is 
often required in men with persistent severe PPI, regardless if bladder dysfunction coexists or 
not. It is not known whether urodynamic bladder dysfunction compromise outcome of 
surgery for PPI. 
For three decades Norwegian patients with persistent severe PPI have been offered 
surgical treatment at the Department of Urology, OUH Rikshospitalet. Since 2012, a few 
other hospitals in Norway also offer such surgery, as the demand for surgical treatment of PPI 
had increased enormously during the previous decade, due to the increased number of RP’s as 
well as increased awareness of the possibility to treat PPI.  
 
Aims of this thesis 
On this background this clinical thesis explores different aspects of PPI in three studies:  
1) How different methods of evaluating PPI result in different prevalence rates in a 
prospective study of 844 patients self-reporting AEs following RP (Paper I) 6.  
2) The associations between preoperative urodynamic findings and outcome of incontinence 
surgery in patients with severe PPI (Paper II) 7.  
3) Generic QOL and risk factors for poor QOL in patients after surgery for PPI (Paper III) 8.  
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 1.2. Aspects of prostate cancer 
 
1.2.1. Anatomy of the prostate gland and surrounding structures 
The prostate gland is primarily an exocrine organ secreting a slightly alkaline fluid that 
usually constitutes about 30% of the volume of ejaculated semen. Its endocrine function 
consists of converting serum testosterone to the more potent androgen dihydrotestosterone by 
the enzyme 5Į-reductase. By convention, the prostate is anatomically divided into transition, 
central, peripheral, and anterior zones, and PCa is usually found in the peripheral zone of the 
gland. 
A thin capsule surrounds the prostate, except from at the apex and base, and a 
multilayered periprostatic fascia is located externally to the capsule. The pubovesical and 
puboprostatic ligaments attach the ventral part of the bladder neck, the urethral sphincter and 
the underlying prostate to the posterior surface of the pubic bone, and these ligaments may be 
important for urinary continence 9.  
The internal and external urinary sphincter and the puborectalis complex of the levator 
ani muscle all contribute to the urinary continence mechanism. The pudendal nerve is somatic 
and supplies nerve fibres via its intrapelvic branch to the striated muscle fibres in the external 
urinary sphincter (the rhabdosphincter) and the levator ani muscle. The preprostatic internal 
sphincter is a continuation of the smooth detrusor muscle and is under alpha-adrenergic 
control with innervation provided by the inferior hypogastric plexus 10. 
The urethral rhabdosphincter is a cylindrical structure surrounding the urethra and 
extending vertically from the perineal membrane to the base of the bladder 11,12. Its muscle 
fibres insert cranially into the apex and anterior face of the prostate gland to merge with fibres 
of the detrusor muscle and caudally into the perineal fascia. This suggests that the action of 
the rhabdosphincter is to draw the sphincteric complex upward beneath the pubic bone. The 
anterior and lateral walls of the rhabdosphincter are thick and rich with striated muscle fibres. 
The posterior wall contains little or no muscle but consists mainly of fibrous connective 
tissue 11,12. These aspects are important also in understanding the pathophysiology of 
incontinence following RP (vide infra). 
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Figure 1. Anatomy of the external striated urethral sphincter (rhabdosphincter) 
(A) Sagittal view of the prostate and bladder in the pelvis.  B) A surgeon’s view of the 
retropubic space. (C) Sagittal view of the sphincter complex in a fresh-frozen cadaveric 
specimen 11. Copyright has been obtained. 
 
 - 10 -
 1.2.2 Prostate cancer epidemiology and risk factors 
Worldwide PCa is the second most frequently diagnosed cancer and the sixth leading cause of 
cancer death in males, accounting for 14% of the total new cancer cases and 6% of the total 
cancer deaths in males in 2008 13. In Europe, PCa is the most common cancer in males 
accounting for 23% of the total new cancer cases, and 10% of all cancer deaths in 2012 14. 
The corresponding proportions for the United States are 27% and 10%, and for Norway 29% 
and 17%, respectively 1. 
PCa incidence rates vary widely, which is likely due to differences both in the true 
underlying prevalence and the intensity of diagnostic efforts. Incidence rates rose rapidly in 
the early 1990s in countries with higher use of PSA-testing, soon after its introduction. 
In Norway, the incidence of PCa has increased four-fold over the last 60 years and 
there were 4,919 new cases in 2012. Of these, 83% had clinically localized or regional 
(locally advanced, vide infra) disease and were potential candidates for curative treatment 15. 
Approximately one in eight Norwegian men will be diagnosed with PCa before the age of 75 
years, most commonly after the age of 50. The mortality rate has been relatively stable with a 
slight decrease the last two decades, lately around 1,000 deaths annually.  
 
 
 
 
Figure 2. Trends in 
prostate cancer 
incidence, mortality, 
and survival, 
Norway, 1965-2012 1. 
Copyright has been 
obtained. 
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 The five-year relative survival rate has increased to 98% for men diagnosed with 
localized PCa, and 92% for all PCa patients in Norway. The 10-year and 15-year relative 
survival rates for all PCa patients are 81% and 73%, respectively 15. Accordingly most men 
die with PCa rather than of PCa. 
Mortality rates may be better estimates of risk and public health significance of PCa 
than incidence rates. High-resource countries usually have a high incidence as well as a 
slightly decreasing mortality (Figure 2), suggesting an effect of earlier detection and/or earlier 
and more effective treatment. However, the increasing incidence and decreasing mortality can 
also partly be due to ‘overdiagnosis’/’overdetection’ 16 which occurs when slow-growing 
cancers are detected, but do not become symptomatic before the patients die of other causes.  
Before the introduction of PSA testing, the incidence-mortality ratio was 2:1. This 
ratio has increased in Western Europe and the USA to 8:1, with a lifetime risk of death due to 
PCa of about 3%, which illustrates the level of overdiagnosis/overdetection of PCa that will 
not cause any harm to the patients’ health 14,17. Autopsy studies have revealed PCa in 31-83% 
of men above 70 years who die from other causes 18.  
The risk factors of developing clinically significant PCa are not well known, although 
three well-established risk factors have been identified: increasing age, ethnicity, and 
heredity 19. 
 Chemoprevention of PCa by medications, dietary nutrients, and supplements, has been 
extensively studied in large prospective randomized trials, however without any results that 
represent basis for any preventive recommendation 20. Lifestyle factors, such as food 
consumption, pattern of sexual behaviour, alcohol consumption, exposure to ultraviolet 
radiation, chronic inflammation, and occupational exposure, might be involved in the 
development of PCa, but there is no evidence to justify recommending lifestyle changes in 
order to reduce the risk of PCa 21.  
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 1.2.3. Prostate Specific Antigen (PSA) 
PSA is a protein secreted from the prostate. The PSA level increases in diseases like benign 
prostate hyperplasia and prostatitis, but also in PCa. PSA testing is therefore used in early 
diagnostics of PCa, although it has low specificity for clinically significant PCa. 
Several modifications of the serum PSA value have been described, which may 
improve the specificity of PSA in the early detection of PCa. These include PSA density, PSA 
density of the transition zone, age-specific reference ranges, PSA molecular forms, and the 
Prostate Health Index (PHI) 22. PSA velocity (rate of rise of PSA level [ng/ml/year]) and PSA 
doubling time have limited use in the diagnosis of PCa as prospective studies have not shown 
superiority over PSA alone 23-25.  
 The widespread use of PSA testing has resulted in a considerable PCa stage migration; 
more men present earlier with lower stages, lower grades, and lower PSA at diagnosis of PCa, 
and fewer men present with incurable metastatic disease. Together with improvements in 
treatment, this has led to significant decrease in PCa mortality in some countries, but also 
overdiagnosis and overtreatment 26.  
With PSA testing and/or screening of healthy men follows an inherent risk of 
overdiagnosis, which is the term used when a condition is diagnosed that would otherwise not 
go on to cause symptoms or death. Overdiagnosis of PCa can be a burden for both the 
individual patient due to AEs and for society due to healthcare costs, when the cancer is non-
progressive or slow growing, as many of screen-detected PCa’s are. In fact, PSA-detected 
cancers might represent overdiagnosis in over 60% 16.  
Screening is defined as “The use of simple tests across a healthy population in order to 
identify individuals who will develop a disease but do not yet have any symptoms” (WHO) 27. 
PSA screening for early PCa detection in asymptomatic men, of any age, without family 
history of PCa, is not recommended in Norway, and there is currently no evidence for 
introducing widespread population-based screening programs in all men in any 
population 19,28. However, from 2002 to 2011, PSA testing rates increased, despite several 
international guidelines that suggest a judicious use of the test 29. In Norway, an elevated PSA, 
as opposed to symptoms or clinical findings (DRE), was the reason for further investigation 
and diagnosing of PCa in 55% of patients in 2012, an increase from around 35% in 2004-
2008 30. 
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 1.2.4. Classification of prostate cancer 
Staging  
The main tools for diagnosing PCa have traditionally been digital rectal examination (DRE), 
serum concentration of PSA, and transrectal ultrasound (TRUS). The need for biopsies is 
determined on the basis of the PSA level, a suspicious DRE finding, the patient’s biologic age, 
any comorbidities, and the therapeutic consequences.  
Clinical tumour, node, metastasis (cTNM) staging is a measure of the anatomical 
extent of the PCa at diagnosis (Table 1) 31. T describes the extent of the primary tumour, N 
describes any metastasis to regional lymph nodes, and M describes any distant metastasis. 
The cTNM stage is one of the most important factors regarding treatment choice and 
prognosis. 
However, the clinical T category (cT), based on DRE, biopsy, and imaging, is 
associated with a high inter-observer variability causing somewhat uncertain classification. 
According to the current European Association of Urology (EAU) guidelines, the imaging 
technique used for local staging should rather be magnetic resonance imaging (MRI) than 
TRUS since MRI improves the detection and characterisation of PCa compared with 
TRUS 19,32.  
Definite statement as to pelvic lymph node status requires lymphadenectomy with 
histopathological examination of the resected tissue. MRI or bone scintigraphy can be used to 
assess metastases in the skeleton, while MRI or computed tomography (CT) can detect 
metastases in soft tissue.  
The EAU guidelines define all non-metastatic PCa as localized, which is also done in 
this thesis. PCa with clinical T category 3-4 is usually specified as locally advanced since the 
PCa of this extension is no longer confined to the prostate 19. However, in the Cancer 
Registry of Norway, localized (cT1-cT2) and regional (i.e. locally advanced, cT3-cT4) PCa 
are registered as separate entities 15.  
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Table 1. The 7th edition of clinical prostate cancer staging 31 
T – Primary tumor 
TX Primary tumor cannot be assessed 
T0 
T1 
T1a 
T1b 
T1c 
No evidence of primary tumor 
Clinically unapparent tumor neither palpable nor visible by imaging 
Tumor incidental histological finding in 5% or less of tissue resected 
Tumor incidental histological finding in more than 5% of tissue resected 
Tumor identified by needle biopsy, but not palpable or visible by imaging 
T2 
T2a 
T2b 
T2c 
Tumor confined within the prostate  
Tumor involves one-half of one lobe or less 
Tumor involves more than one-half of one lobe, but not both lobes 
Tumor involves both lobes 
T3 
T3a 
T3b 
T4 
Tumor extends through the prostatic capsule 
Extracapsular extension (unilateral or bilateral) 
Tumor invades seminal vesicle(s) 
Tumor is fixed or invades adjacent structures other than seminal vesicles 1  
N – Regional lymph nodes 2 
NX 
N0 
N1 
Regional lymph nodes not assessed  
No regional lymph node metastasis 
Metastasis in regional lymph node(s)  
M – Distant metastases 3 
MX 
M0 
M1 
M1a 
M1b 
M1c 
Distant metastasis not assessed 
No distant metastasis 
Distant metastasis 
Non-regional lymph node(s) 
Bone(s) 
Other site(s) with or without bone disease 
1  External sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
2 Regional lymph nodes (extended lymph node dissection): obturator, external iliac, and 
hypogastric (presacral) 
3 When more than one site of metastasis is present, the most advanced category should be used 
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 Grading 
The Gleason score (1966), named after the American pathologist Donald Gleason (1920-
2008), is recommended for histopathological grading of PCa and has proved to be important 
as prognostic factor 19,33,34. Gleason graded PCa on a scale from 1 to 5 (Figure 3). According 
to current international convention, the Gleason score of a prostate biopsy consists of the 
Gleason grade of the most extensive carcinoma plus the highest grade, regardless of its extent, 
as opposed to the original scoring system that added the most common and second most 
common pattern 19,35.  
The ability to distinguish aggressive from indolent PCa is of great importance to refine 
PCa detection, decision-making, and care. Epstein et al. identified histological criteria in 
prostate biopsy specimens that discriminate indolent from clinically significant PCa 36. The 
histological criteria that define indolent PCa on biopsy include absence of Gleason grade 4 or 
5, PCa limited to three or fewer biopsy cores, and <50% tumor involvement in any individual 
core 37. These criteria have been used for inclusion to active surveillance, with the aim of 
deferring active treatment when not necessary (vide infra).  
 
Figure 3. 
Gleason grades 1 to 5 38 
Copyright has been 
obtained.
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 Risk stratification 
PCa risk groups are useful in treatment decision-making and reporting of outcomes. The PCa 
risk groups are based on pre-treatment PSA, clinical T-category, and Gleason score of 
prostate biopsies in patients with localized PCa (i.e. non-metastasized) 39. However, as 
described above, the role of the clinical T category in these criteria remains controversial. 
There are several ways to define risk groups of localized PCa, with some minor 
differences (Table 2). The D’Amico risk groups have been widely adopted 40, and they have 
been shown to predict PCa-specific survival in patients undergoing curative treatment of 
PCa 41,42.  
i Low-risk PCa according to D’Amico is defined as cT1-2a (tumor involving one-
half of one lobe or less) and PSA 10 ng/ml and Gleason score <7.  
i Intermediate-risk PCa is defined as cT2b (tumor involving more than one-half of 
one lobe, but not both lobes) or Gleason score 7 or PSA >10-20 ng/ml.  
i High-risk PCa is defined as cT2-T3a (tumor involving both lobes, with or without 
extracapsular extension, but not the seminal vesicles) or PSA >20 ng/ml or 
Gleason score >7 43.  
The current EAU guidelines have slightly different cut-offs than those originally described by 
D’Amico (Table 2) 19.  
  
Table 2. Defined risk groups of localized prostate cancer 39 
 Very low-risk Low-risk Intermediate-risk High-risk 
D’Amico 40,43  PSA 10 (a) 
and GS <7 (b) 
and cT1-2a (c) 
PSA >10-20, 
or GS 7, 
or cT2b 
PSA >20, 
or GS >7, 
or cT2c-3a 
EAU 19  PSA <10, 
and GS <7,  
and cT1c 
PSA 10-20, 
or GS 7,  
or cT2b-2c 
PSA >20,  
or GS 8-10,  
or  cT3a 
NCCN (d)  39 cT1c  
GS < 7  
PSA < 10 
PSAD < 0.15 (e)  
<3 pos. biopsies 
PSA <10, 
and GS <7,  
and cT1-2a 
PSA 10-20, 
or GS 7,  
or cT2b-2c 
PSA >20, 
or GS >7,  
or cT3a 
aPSA: Prostate Specific Antigen (ng/mL) bGS: Gleason score. c cT: clinical T stage.  d NCCN: National Comprehensive 
Cancer Network. ePSAD: Prostate Specific Antigen Density (a quotient of PSA and prostate volume). 
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 1.2.5. Treatment of clinically localized prostate cancer 
Overview
The natural history of low-risk PCa is such that the vast majority of affected men will die 
from other causes than PCa, even without curative treatment of the PCa 42. However, it is 
well-documented that the long-term survival is considerably diminished in men diagnosed 
with intermediate or high-risk PCa 42,44,44. 
The established curative treatment options for localized PCa are radical prostatectomy 
(RP) and radiation therapy (RT) with comparable oncologic outcomes and long-term survival, 
although randomised studies have not been performed. However, active surveillance (AS), 
watchful waiting (WW), or non-curative hormone-treatment are also available options for 
some patients with clinically localized PCa. High-intensity focused ultrasound (HIFU) and 
cryotherapy have emerged as new alternatives for treating localized PCa, but there is not 
enough data available to give treatment recommendations 45,46. 
Of all men diagnosed with PCa in Norway in 2012, 6% were assigned to AS, 35% 
underwent RP, and 24% received RT 30. The proportion that underwent local tumor 
destruction (predominantly HIFU in Norway) was not reported. In Norway the PCa patient is 
not always evaluated in a multi-disciplinary team in the diagnostic period, but often evaluated 
and counselled by the urologist alone, which could to some extent explain the higher use of 
RP than RT. 
 
 
 
 
 
 
 
 
 
Figure 4. Proportion of 
PCa patients undergoing 
RP (‘prostatektomi’),  
RT (‘strålebehandling’) 
and AS (‘aktiv 
overvåking’) in Norway 30  
Copyright has been 
obtained. 
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 The treatment decision may have long-term implications as each treatment modality is 
associated with a distinctive pattern of adverse effects (AEs) 2. While erectile dysfunction and 
urinary incontinence are more common after RP, urinary irritative symptoms and bowel 
dysfunction are more common after RT. Therefore, treatment choices should be determined 
with care in a dialogue between the doctor and the patient, having in mind that curatively 
intended treatment is not always indicated. 
 
Active surveillance and watchful waiting 
Active surveillance (AS) is an option for patients with low-risk PCa and good performance 
status. Studies on AS in clinically organ-confined PCa have shown a low rate of progression 
and PCa-specific death in well-selected patients with low-risk disease. The aim is to reduce 
overtreatment in patients with clinically confined low-risk PCa, holding the option of curative 
treatment in reserve. The idea was originally based on data demonstrating that men with well-
differentiated (i.e. low grade) PCa have a 20-year PCa-specific survival rate of 80-90% 47,48. 
AS might mean no treatment at all for patients above 70 years or patients with a life 
expectancy of less than 10 years, while AS in younger patients might mean a possible 
treatment delayed for years.  
According to Norwegian guidelines, patients with low-risk PCa should be 
recommended AS after MRI has been performed 45. Criteria are low-risk PCa (D’Amico) 
with two or less positive biopsies of at least 8 biopsies, and less than 50% cancer of normal 
biopsy length. In Norway, AS has not yet become widely accepted as a valid strategy for 
these men, however. The proportion of patients with low-risk PCa included in AS increased 
from almost 20% to over 30% in the period 2009-2012, with a similar trend in the United 
States 49, while the corresponding proportion in Sweden is 65% 30. At different hospitals in 
Norway, this proportion varied from less than 30% to 95% 50. Although the proportion is 
slowly increasing, there has been a challenge communicating that this is a safe alternative for 
selected patients. 
 In patients with PCa not eligible for curative treatment due to old age or comorbidity, 
watchful waiting (WW) can be a suitable approach of conservative management. WW means 
that patients remain without treatment until symptoms occur, and will at that time be offered 
palliative treatment (hormone treatment, transurethral resection of the prostate and/or RT).  
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 Radical prostatectomy 
For men with clinically localized PCa that is clinically significant, i.e. intermediate-risk and 
high-risk PCa, and who have a life expectancy of at least 10 years, surgery is one of the 
relevant options for curative treatment. The goal of RP is eradication of the PCa by complete 
removal of the prostate gland and the seminal vesicles with tumour-free surgical margins and 
preservation of urinary continence and erectile function. The so-called “trifecta outcome” 
implies that the patient ideally is cancer free, continent and potent after RP. An extended 
concept, the “pentafecta”, includes the trifecta as well as negative surgical margins and no 
surgical complications 51. 
Potential benefits of RP include more than 10 to 15 year disease-free survival when 
the PCa is localized, better determination of prognosis with pathological staging, and good 
outcomes with postoperative RT in the adjuvant or salvage setting.  
Prior to the 1980’s, the surgical anatomy of the prostate and surrounding tissue was 
poorly understood and the complication rates were high due to intraoperative bleeding and 
high incidence of postoperative incontinence, erectile dysfunction, and stricture formation 52. 
After the description of the anatomy of the dorsal vein complex 53 and the pelvic plexus 
innervating the corpora cavernosa 54, as well as further description of the pelvic anatomy 55, 
the operative technique of RP was refined within the following two decades. This led to better 
preservation of urinary continence and erectile function, and hence substantially increased the 
use of surgery as treatment for localized PCa (Figure 5) 52,56.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Change of 
incidence of PCa 
treatment modalities 
over time (USA) 56.  
Copyright has been 
obtained. 
   
 - 20 -
 Perineal RP was first described by the German surgeon Theodor Billroth in 1867 and 
retropubic RP (RRP) was introduced by the British surgeon Terence Millin in 1947 57,58. With 
the incorporation of laparoscopy in urologic surgery, surgeons in Europe were the first to 
describe the technique and early outcomes with laparoscopic radical prostatectomy (LRP) 59. 
However, LRP is technically demanding with a long learning curve. As an alternative the 
robot-assisted radical prostatectomy (RARP) was developed at Henry Ford Hospital; Detroit, 
MI, in 2000 60. The telepresence technology was first meant to be used in the military, but 
was commercialized by the American company Intuitive Surgical into the system called the 
daVinci surgical system 61. The big advantage over laparoscopy was better movement of the 
instruments, that have an extra ‘joint’ intracorporally, which is of essential value when 
suturing in the pelvis. Nevertheless, the learning curve for RARP is not as short as previously 
thought, and a large number of cases is needed to get positive surgical margin (PSM) rates 
and operative time to a minimum 62. 
During the last decade there has been a tremendous growth in adoption of the robot-
assisted procedure despite limited data on outcomes and greater costs compared with open 
RRP. In spite of that, RARP is the first robot-assisted surgical procedure to achieve 
widespread use, and has become the primary approach for the surgical management of 
localized PCa in the United States 63,64. With limited follow-up time and lack of randomized 
controlled trials, available data suggest that there are similar complications rates, oncologic 
outcomes, and AEs (incontinence and erectile dysfunction rates) following RARP, RRP and 
LRP 65-67. 
In Norway, the first daVinci surgical system was established at the Department of 
Urology, OUH Radiumhospitalet, in December 2004 as the second in Scandinavia, and since 
2005 no open RP have been done at that department. RARP is currently available at eight 
hospitals in Norway. 
 Nerve-sparing RP should be attempted in all men with normal or near-normal 
preoperative erectile function and organ-confined disease, whether by RRP or RARP, while 
unilateral nerve sparing procedure is an option in stage T2a-T3a disease 19,68.  
 The need for and the extent of pelvic lymphadenectomy are controversial. The risk of 
lymph node metastases is low in men with low-risk PCa and <50% positive biopsy cores 69,70. 
Surgery for high-risk prostate cancer should aim at achieving either oncological radicality or 
local debulking, both of which include an extended pelvic lymph node dissection, not only for 
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 staging purposes, but also with a possible therapeutic intent 71. Norwegian guidelines 
recommend bilateral extended lymphadenectomy in patients with high-risk PCa and if 
surgical lymph node (N) staging is indicated 45. 
There are diverse opinions regarding the optimal treatment of men with high-risk, 
clinically localized PCa and management should be discussed in an interdisciplinary team, 
due to the high risk of positive surgical margins (33-66%) and regional lymph node 
metastasis (8-49%). Of patients primarily treated with surgery 56-78% eventually require 
adjuvant or salvage RT or hormonal therapy 19. On the contrary, about 40% of the patients 
with high-risk PCa undergoing RP have specimen-confined disease (pT2–pT3a, pN0, and 
negative surgical margins), and they have excellent long-term outcome 72. There is also an 
increasing trend towards using surgical therapy to address locally advanced PCa (cT3) with 
simultaneous extended lymphadenectomy in selected cases 45,73,74.  
 
Follow-up
In Norway, following RP, the first postoperative visit with the operating surgeon is normally 
scheduled within six weeks after RP when serum PSA is measured and the oncological 
outcome (prostate specimen histopathology) reviewed. Any need for adjuvant RT is 
considered at that time 45. Evaluation of possible long-term AEs should also be done and 
treatment, including penile rehabilitation, applied when indicated. Further follow-up at 3, 6, 
and 12 months are carried out by the urologist or the patients’ regular general practitioner 
(GP) 45. 
PCa patients are usually followed by their regular GP for at least 10 years or until high 
age makes follow-up redundant. Determination of serum PSA, together with disease-specific 
history, is supplemented by DRE and by imaging studies if locally recurrent disease is 
suspected 19,45. A detectable PSA following RP implies residual or recurrent PCa. Usually, the 
cut-off value in the definition of biochemical recurrence (BCR) after RP is set at PSA of 
0.2 ng/ml 45,75. 
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 Adjuvant and salvage treatment following RP 
Adjuvant treatment is applied after initial treatment for cancer, to suppress the risk of BCR 
and metastases. Salvage treatment is on the other hand applied after evidence of BCR, as 
secondary treatment.  
Patients, who have undergone RP with positive surgical margins (PSM) and/or 
invasion of the seminal vesicles, in spite of an unmeasurable PSA postoperatively, have a 
high risk of local recurrence. They can be offered either immediate RT (adjuvant RT) to the 
surgical bed on recovery of urinary function, or PSA monitoring and salvage RT after BCR. 
Of patients with high-risk PCa in Norway in 2012, 21% had postoperative RT within 300 
days of RP, and almost 50% had postoperative RT if there were positive surgical margins in 
the removed prostate specimen 30. For intermediate-risk and low-risk PCa, 8% and 4% had 
postoperative RT, respectively.  
The optimal timing and treatment choice for patients with BCR after RP remain 
controversial however, as the survival benefit for salvage treatments has not been clearly 
established. Available data indicate that if salvage RT is commenced before PSA reaches 0.5 
ng/ml, the oncological outcomes are comparable with adjuvant RT. Adjuvant RT or early 
salvage RT (PSA <0.2 ng/ml) impose a risk of overtreatment with subsequent increased risk 
of urethral strictures, urinary incontinence and erectile dysfunction 76. However, the starting 
point of salvage RT remains to be set, probably somewhere in the range of PSA 0.2-0.5 ng/ml. 
Possibly, more complex criteria combining PSA doubling time, Gleason score, and 
preoperational PSA may be taken into account before initiation of salvage RT in the future.  
Adjuvant androgen deprivation therapy (ADT) following RP has always been 
controversial. It is probably indicated in patients with microscopic lymph node involvement, 
especially when there are positive surgical margins and seminal vesicle involvement. 
However, it is not known if patients with only minimal nodal involvement have any benefit of 
adjuvant ADT 19,45. In selected patients, only follow-up of PSA, and delayed start of ADT in 
case of a rising PSA level, is therefore acceptable. 
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 1.2.6. Survival and prognosis  
The most relevant outcome measures after curative treatment of localized PCa are PCa-
specific and overall survival rates which require at least 10 years of observation time to be 
meaningful. However, the most commonly reported measure of cancer control following RP 
has been biochemical recurrence (BCR) (definition of BCR, see p.22).  
Two randomized controlled trials comparing radical prostatectomy with watchful 
waiting have been conducted. The Scandinavian Prostate Cancer Group (SPCG)-4 trial was 
the first to show that RP reduced PCa mortality and risk of metastases compared to WW in 
patients with clinically localized, low- or intermediate-risk PCa 77. At 18 years follow-up 
patients who underwent RP had significantly lower overall mortality (56% vs. 69%, 
RR=0.71), lower PCa specific mortality (18% vs. 29%, RR=0.56), and lower risk of 
developing metastatic disease (26% vs. 38% RR=0.57) compared with WW 78. The benefit 
was greatest in men under 65 years of age and those with intermediate-risk PCa. The number 
of patients needed to treat to prevent one death was 8 in the whole cohort and 4 among men 
under 65. This study began after PSA testing had been introduced into clinical practice but 
only 5% of men with PCa were diagnosed after a PSA test. 
 The Prostate Cancer Intervention Versus Observation Trial (PIVOT) also randomized 
patients to WW or RP 79. After a mean follow-up of 10 years, there were no statistically 
significant differences in mortality, overall survival, and PCa-specific survival. Only patients 
with a pre-treatment PSA >10 or high-risk PCa experienced a significant benefit in overall 
survival. 
 Retrospective analyses of men treated during the PSA era have shown good cancer 
control, but the impact of RP cannot be determined due to the study design and the lack of 
control groups. Nevertheless, Boorjian et al. reported a 10-year PCa-specific survival of 
99.7%, 97%, and 95% after RP for D’Amico low-, intermediate-, and high-risk PCa, 
respectively, and Hull et al. reported a mean 10-year PCa-specific survival of 97.6% after 
RP 40,80. A recent review of RP for high-risk (of various definitions) PCa, showed that RP 
with extended pelvic lymphadenectomy is associated very good cancer-related outcomes, 
especially in specimen-confined disease, although often with multimodal treatment 74. In 
conclusion, these data have the limitations of retrospective studies, but show that most 
patients with localized PCa will live many years following RP. 
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 1.3. Adverse effects and quality of life after radical prostatectomy 
 
1.3.1. Assessment of adverse effects and quality of life 
General considerations 
More knowledge of PCa treatment outcomes is important to both patients and clinicians, 
since possible long-term adverse effects (AEs) are important for the choice of primary 
treatment. The concept of outcome assessment after cancer treatment has been expanded from 
exclusive reliance on objective clinical parameters (PSM rates, time to BCR, survival time, 
etc.) to a broader assessment that includes patients’ subjective evaluation of their physical, 
mental, and social well-being and overall satisfaction with life as well as self-reported AEs 
and their impact on quality of life (QOL). Many symptoms and functions are not measurable 
with laboratory tests or doctors’ ratings, and therefore it is necessary to rely on the patients’ 
self-reports. Some examples are role functioning, social functioning, sense of well-being, pain, 
fatigue, sexual function and impact of urinary incontinence. It is therefore essential to include 
self-report of AEs and QOL as part of the outcome assessment after treatment of PCa.  
 There are differences of opinion on what the term QOL actually implies. For many 
urologists, QOL is the same as AEs (so-called disease-specific QOL) 81. However, other 
urologists consider QOL and AEs as independent concepts, well aware of the impact of AEs 
on a patient’s degree of QOL (generic/health-related QOL).  
QOL related to for example urological problems only, focusing on the patients’ well-
being related to urinary symptoms affecting daily activities, could be referred to as 
incontinence-related QOL. Such organ-specific evaluation of QOL is different from that of 
generic or health-related QOL, covering aspects of physical, emotional and mental well-being. 
This has been increasingly recognized after Litwin introduced generic QOL measurements 
with the Short Form 36 (SF-36) questionnaire as a supplement to the University of California 
Los Angeles Prostate Cancer Index (UCLA-PCI, 1995) instrument for patient-reported AEs 
after treatment for PCa 82.  
To conclude on this issue, QOL can be divided into three concepts: Global QOL 
(overall satisfaction with life), generic QOL (includes physical, mental, and social well-
being), and disease-specific QOL (includes AEs after cancer treatment). Moreover, the term 
health-related QOL (HR-QOL) is often referred to when addressing either of the latter two. 
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 The timing at which a survey of QOL and AEs is performed is of great importance and 
is especially crucial to consider when comparing studies of AEs after cancer treatment. We 
distinguish between acute, chronic/long-term and late AEs of treatment. The term “late 
effects” includes AEs appearing more than a year after treatment.  
AEs can theoretically be evaluated and measured by an external observer (health care 
professional or spouse) or by the patient himself. Previously the evaluation of AEs often 
relied primarily on the physicians’ evaluation of symptoms at follow-up visits. However, 
physician-reported ratings do not include assessment of a wide variety of patient-experienced 
subjective symptoms affecting the daily well-being. In general, patients report more frequent 
and severe AEs than their physicians 83,84. Therefore, since the 1990’s patient-reported 
outcomes (PRO) have been increasingly recognized as valid measures of treatment 
consequences. There is now a general consensus that the assessment of AEs should primarily 
be based on patient-report rather than physician-report. Patient-reported outcome 
measurements (PROM) are nowadays part of routine assessment in clinical cancer research to 
provide added value to traditional clinical outcomes 85-87.  
There are several instruments available designed to evaluate patients’ function and 
bother in relation to PCa treatment, but there is currently no consensus as to the best 
instrument or method for evaluating changes from baseline (pre-treatment) to post-treatment. 
Clinical significance is therefore not a given fact when using PROM but is important to 
consider when analyzing and interpreting PROM data and measuring changes. The question 
of how much change for a single patient or difference between treatment outcomes is 
considered to be statistically and clinically significant is still unanswered. The FDA 
guidance 88 has moved away from recommending the use of the ‘minimally important 
difference’ 89. Other guidelines propose that a change of 10 points on a 0–100 scale is a 
sufficient change to have clinical meaning 90,91. This magnitude is about the same as the 0.5 
standard deviation (SD) that has been suggested as being universally acceptable 92. 
Measuring effect size (ES) is a different approach to analyze and interpret 
differences/changes into clinical significance. Cohen considered ES values 0.40 as clinically 
significant when group means are compared 93,94. 
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 Questionnaires 
The University of California Los Angeles Prostate Cancer Index (UCLA-PCI) questionnaire 
with 20 items was specifically developed to assess typical AEs after treatment for PCa 82. The 
Expanded Prostate Cancer Index Composite with 50 items (EPIC-50) is a modified and 
extended version of the UCLA-PCI and includes items to capture additional concerns relevant 
to RP, RT, and androgen deprivation 95. Later an abbreviated version with 26 items has been 
developed (EPIC-26) 96. The EPIC questionnaires rate the patients’ experiences of urinary, 
sexual, bowel, and hormonal functions, and bother (problems) related to each specific 
function, and overall problems.  
Other examples of instruments assessing AEs after PCa treatment are the European 
Organization for Research and Treatment of Cancer PCa module (EORTC QLQ-PR25), the 
Prostate Cancer Symptom Scale (PCSS, formerly named QUFW94) and the Functional 
Assessment of Cancer Therapy-Prostate (FACT-P) 97.  
The EPIC questionnaires were recently assessed as the best questionnaires available 
regarding the evaluation of AEs in PCa patients 98. The International Consortium for Health 
Outcomes Measurement (ICHOM) recently published guidelines for localized PCa where the 
EPIC-26 is the recommended instrument for assessment of AEs. The recommended timing is 
before and 6 months after PCa treatment and then annually up to 10 year follow-up 99.  
The abovementioned AE-specific instruments are often combined with generic QOL 
instruments 100. Litwin introduced generic QOL measurements with the Short Form 36 
(SF-36) together with his UCLA-PCI instrument. The SF-36 is intended to measure “general 
health concepts not specific to any age, disease, or treatment group” 101. 
Later, the SF-36 was supplemented with the shorter SF-12 that contains physical and 
mental composite scores, as expression of the two different aspects of QOL 102. The SF-12 is 
the instrument recommended for the rating of generic QOL in PCa patients based on its good 
psychometric properties 97 and should ideally be assessed simultaneously with the EAs, 
before and after treatment. 
 
 - 27 -
 1.3.2. Common adverse effects after radical prostatectomy 
RP is followed by a specific pattern of persisting “typical” AEs that may become long-term 
AEs lasting more than a year after RP. The most frequent and bothersome AEs are erectile 
dysfunction (ED) and urinary incontinence, which are considerably more common than after 
RT 2,103-105. Other sexual and urinary dysfunctions than ED and incontinence may also occur. 
For patients who have undergone RP, generic QOL and chronic fatigue are probably 
in the range of the normal population, and better than patients who have undergone RT 104,106-
108. However, it has been shown that AEs after RP have a negative impact on generic 
QOL 103,109. And for some patients, persistent urinary incontinence negatively influence their 
work life 110,111.  
 
Urinary adverse effects 
RP may cause damage to the bladder, urethra and surrounding tissue, including blood vessels 
and nerves. Patients with PCa and an enlarged prostate may have urinary symptoms before 
RP, usually obstructive symptoms like weak flow, incomplete emptying, post-micturition 
dribble, and irritative symptoms like frequency, nocturia, urgency and urgency urinary 
incontinence (UUI). The prevalence of incontinence before RP has been shown to be 13% 
and the prevalence of irritative/obstructive symptoms 36% 112,113 After RP, any previous 
obstructive symptoms are likely to be replaced by storage symptoms in the form of stress 
urinary incontinence (SUI). Irritative/obstructive symptoms may prevail or be relieved 
following RP, probably depending on the degree and duration of any previous obstruction 5.  
 Following removal of the prostate and anastomosis of urethra and bladder neck during 
RP, patients have an indwelling catheter for 1-2 weeks. Immediately after catheter-removal 
there is a high rate of urinary incontinence, which improves gradually over the next 12-24 
months. The most significant improvement occurs three months following surgery 112. 
Postprostatectomy incontinence (PPI) is the most frequent urinary AE, caused by 
intrinsic sphincter deficiency (ISD) mostly, and/or detrusor overactivity (DO) in some cases. 
Patient-reported PPI (‘any urinary leakage’) is present in up to 87% of patients after RP, and 
persistent long-term PPI has been reported in 40% 114,115.  
Advancing age is an established risk factor for PPI, but there is some controversy to 
whether comorbidity, high PCa stage, lack of nerve sparing, or blood loss are associated with 
the risk of PPI 115. Other potential risk factors include high BMI, low socioeconomic status, 
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 non-black race, high education level, high PSA, high Gleason score, high prostate volume, 
and preoperative incontinence and erectile dysfunction 67,115-117. Men who undergo salvage 
surgery or salvage RT for recurrent PCa have a higher risk of incontinence 118. 
Conservative management of PPI includes lifestyle interventions, pelvic floor muscle 
training (PFMT) with or without biofeedback, and bladder training 67. In patients with 
symptoms of bladder dysfunction, additional anticholinergic medication is the recommended 
first-line treatment for early PPI. For persistent, severe PPI after conservative treatment has 
failed, surgical treatment is available. Up to 10% of patients with PPI will need surgical 
treatment of their urinary leakage 67. Put in another way, the proportion of patients following 
RP requiring surgery for PPI is 5%-9% 114,115,115,119. 
 Long-term urinary AEs, definitions, assessment, and treatment, will be discussed in 
more detail later (Chapter 1.3.3.-1.3.5.). 
 
Sexual adverse effects 
Sexual AEs after RP are complex, as sexual function depends on both physiological and 
psychological factors. Individual factors like age, education, comorbidity, diabetes mellitus, 
BMI, general health, preoperative sexual function, as well as partner-related factors influence 
postoperative sexual function and the subjective experience of sexual bother 120-122. As many 
as 45%-64% of RP candidates suffer from erectile dysfunction (ED) preoperatively 122. Other 
potential risk factors for sexual AEs, apart from treatment modality and nerve sparing during 
RP, include advanced PCa stage and high PSA prior to treatment 121-123.  
Considering only preoperatively potent patients, recovery of erectile function with 
nerve-sparing procedures one year after RP varies between 31% and 90% 121,122,124,125. 
Norwegian studies have shown that 60%-90% of PCa patients have ED following RP, 
disregarding nerve-sparing technique 126,127.  
Recovery of erectile function may be slow over the course of more than two 
years 63,122. Penile rehabilitation strategies have been developed with the goal of increasing 
the probability and speed of return of erectile function 128. Regular administration of per oral 
phosphodiesterase type 5 (PDE-5) inhibitors, creation of erections with vacuum devices, or 
intracavernosal injection of vasocative agents (papaverine-phentolamine, alprostadil) 
improves the probability of recovering erectile function, probably by preventing prolonged 
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 ischemia thereby preserving the smooth muscle tissue and function of the corpora 
cavernosa 128-130.  
In Norwegian national PCa guidelines this aspect of follow-up is hardly mentioned 45. 
Most urological departments have some form of local guidelines on penile rehabilitation, 
although these are followed to varying degrees. 
 
Quality of life (QOL) 
There is conflicting evidence in the literature regarding the impact of PCa treatments and AEs 
on QOL. AEs after treatment for PCa, such as urinary and sexual dysfunction, which is 
associated with reduced disease-specific QOL, can also have an impact on generic QOL. 
Generic QOL assessments of the AEs following RP have shown, in the past, that major 
domains such as physical, emotional and social functioning seem not to be affected or to 
recover within a short time after RP 107. However, in their large Prostate Cancer Outcomes 
Study (PCOS), based on the Surveillance, Epidemiology, and End Results (SEER) program, 
Penson et al. showed that AEs, such as urinary function and bother, and sexual function and 
bother, were independently associated with reduced generic QOL 109.  
A recent systematic review of QOL outcomes following RP report similar or 
improved general QOL (using the SF-36), and no observable difference between men 
undergoing RP, RT, men electing AS, and control subjects 122.
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 1.3.3. Pathophysiology of urinary dysfunction following radical prostatectomy 
The lower urinary tract has two missions: protecting the kidneys while maintaining a social 
function, both of which involve well-functioning storage most of the day and periodic voiding 
at the right time and place. The storage and voiding of urine depend on the coordinated 
activity of smooth and striated muscles in the two functional units of the lower urinary tract, 
the bladder and the outlet (in males consisting of the bladder neck, the prostate, the urethra, 
and the urethral sphincter). In the healthy male, all parts of the outlet are important for the 
continence mechanism, along with a normal bladder function. The lower urinary tract is 
different from other internal organs under autonomic control in that it has only two modes of 
operation: storage and voiding, i.e. activity that is turned on or off, not a continuous tonic 
pattern like the GI tract or cardiovascular system 131.  
Hence, based on these two modes, lower urinary tract dysfunction (LUTD) has 
traditionally been divided into two major categories; dysfunctional storage/filling phase and 
dysfunctional voiding phase. Dysfunctional storage can be characterized by incontinence or 
so-called irritative/obstructive symptoms like urgency and frequency. Dysfunctional voiding 
phase with slow and/or incomplete emptying of the bladder can be caused by an underactive 
detrusor or bladder outlet obstruction. (The latter will not be commented to depth in this 
thesis.) In addition, post-micturition symptoms are sometimes referred to as a third category. 
Urinary dysfunction following RP can comprise all of the above. Thus, as mentioned 
briefly previously, postprostatectomy incontinence (PPI) is potentially caused by either 
intrinsic sphincter deficiency (ISD), detrusor overactivity (DO), or both. Classically, ISD is 
associated with the symptom of stress urinary incontinence (SUI) and DO is associated with 
the symptom of urgency urinary incontinence (UUI). Although incontinence may well be 
present before RP, preoperative incontinence is usually characterized by UUI and/or post-
micturition dribble, due to DO and incomplete emptying secondary to obstruction, rather than 
SUI due to ISD. 
ISD can be caused by damage to the urethral sphincter through direct injury, or injury 
to the nerve supply or the supporting structures. The bladder neck and the prostate are 
important contributors to the continence mechanism and are damaged and extirpated during 
RP. Along with direct and/or indirect damage to the urethral sphincter, supporting structures, 
blood supply and nerves, ISD may be the result. Reduced blood flow to the urethra is 
associated with a lower urethral pressure 132,133, which in turn is associated with ISD 134.  
 - 31 -
 These damages can cause ‘urethral hypermobility’ as well as ‘true intrinsic sphincter 
deficiency’ of the rhabdosphincter 134. The ‘hypermobility’ is a displacement of the urethra 
during sudden increase in abdominal pressure which decreases pressure transmission, a 
theory not completely free from controversy 135. ‘True’ ISD is when the urethra is unable to 
generate enough outlet resistance to keep the urethra closed at rest or with minimal physical 
activity 134.  
Bladder dysfunction after RP may be represented not only by DO, but also by low 
bladder compliance and/or impaired detrusor contractility (detrusor underactivity). However, 
bladder dysfunctions may be present without giving any symptoms, especially if present 
together with ISD 136. 
Although there is extensive literature on urinary incontinence after RP, there is little 
data on bladder function after RP. Bladder dysfunctions may occur de novo following bladder 
denervation during surgery, be induced by pre-existing long-term bladder outlet obstruction, 
or be a consequence of bladder ageing 137. Most published reports agree that DO may 
aggravate PPI, but rarely is the primary cause of PPI. However, it is not clear whether the 
anatomic dissection during surgery affects both the storage/filling phase and the 
voiding/micturition phase.  
Irritative/obstructive symptoms, i.e. symptoms indicative of bladder dysfunction or 
obstruction (prostate enlargement preoperatively, anastomosis stenosis postoperatively), 
usually improve after RP. Lepor and Kaci were the first to show that patients with 
irritative/obstructive symptoms before RP have a moderate improvement one year after RP 112. 
Others have shown the same effect lasting for up to five and ten years after RP 138.  
The wide anatomic dissection around the prostate during surgery can damage the 
afferent and efferent innervation of the trigone, rhabdosphincter, bladder neck, and posterior 
urethra, with resulting insufficiency of the continence mechanism and partial denervation of 
the detrusor muscle 5. Modifications of the surgical techniques and postoperative patient care 
have been proposed in an attempt to improve the continence rates after RP.  
The nerve sparing technique by Walsh for preservation of erectile function, 
popularized in the 1990’s, produced early data indicating that the technique may also result in 
improved rates of continence by preserving neural innervation to the rhabdosphincter at the 
time of RP 68,139,140. Continence nerves contained in the neurovascular bundles can be 
damaged by blunt dissection with clamping of posterior periurethral tissues beneath the 
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 urethra at the prostatic apex, and sutures placed at the 5 and 7 o’clock positions for 
vesicourethral anastomosis 11. Moreover, dissection of the seminal vesicle can injure the 
pelvic nerve plexus, which is located on the lateral surface of the rectum with its midpoint at 
the tip of the seminal vesicles and provides autonomic innervation to all pelvic organs. 
Finally, to preserve urinary continence after RP, preservation of the entire 
circumferential rhabdosphincter musculature and the fascial tissues, especially giving 
attention to restoration of the posterior aspect of the rhabdosphincter and to the innervation of 
both the rhabdosphincter and the mucosal and the smooth muscle components have been 
suggested 11,12,141. In ‘posterior reconstruction’, the posterior rhabdosphincter is joined to the 
posterior Denonvilliers’ fascia and fixed to the bladder wall 1-2 cm cranial to the new bladder 
neck to avoid caudal retraction of the sphincteric complex, prior to completing the standard 
vesicourethral anastomosis 12,12,142. This technique was first described by Rocco et al. in 2001, 
and served as a basis for newer additional modifications 63. 
Further advances and suggestions include anterior reconstruction/suspension, fascial 
sling construction, bladder neck preservation, intraoperative cooling, and pubovesical 
complex-sparing 63. However, as we still lack international consensus on standardization of 
outcome definitions (such as continence), the effect/benefit of these recent modifications have 
been difficult to document and have therefore been somewhat controversial.  
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 1.3.4. Terminology and assessment of urinary dysfunction 
Assessment of urinary dysfunction can be done with several methods:  
1) By self-report (standardized questionnaires) assessing symptoms and related bother.   
2) A focused clinical history using standardized terminology 143 can provide a great deal 
of valuable information and details.  
3) Urinary diaries and pad tests give an indication of the severity of the urinary 
dysfunction(s).  
4) Non-invasive clinical examinations such as free uroflowmetry and ultrasound for 
post-void residual urine measurement.  
5) Invasive clinical methods including urodynamics and cystoscopy. 
 
Patient reported urinary symptoms 
The International Continence Society (ICS) published an updated version of ‘The 
Standardisation of Terminology of Lower Urinary Tract Function’ in 2002. The report 
presented definitions of symptoms, signs, urodynamic observations and conditions associated 
with lower urinary tract dysfunction (LUTD) and set the gold standard of terminology in the 
field 115,143,144. A short review was published in 2009 145.  
Urinary incontinence is defined by ICS as ‘the complaint of any involuntary leakage 
of urine’ 143. The most common definition of incontinence following RP used in the medical 
literature though, is ‘any use of pads’ 146. However, this definition excludes patients who 
report any leakage (without pad use), which can be a significant proportion of patients who 
have undergone RP. Up to 50% of men who do not use pads have occasional leakage of urine 
after RP 115,147. Herschorn et al. have presented three definitions of urinary continence 115:  
1) Total control/perfect continence.  
2) Occasional leakage but no pad.  
3) Less than one pad/no or one (0-1) pad per day.  
These definitions of different levels of leakage are commonly used when reporting continence 
and/or incontinence following RP. The differences in definitions contribute to the wide 
variety in reported prevalence rates of PPI 3,4. Liss et al. (2010) proposed that continence 
should be strictly defined as no pads, not 0-1 pad, based on their findings that patients who 
use pads, even just one ‘security pad’, have significantly lower QOL compared with patients 
who do not use pads at all 148. However, when comparing correspondence among continence 
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 definitions (using the UCLA-PCI questionnaire), Krupski et al. found that only 42% of 
patients who reported using no pads did not leak urine at all 4.  
Validated symptom scales with several items of objective (pad use) and subjective 
(bother) experience, like the EPIC-26, may be useful when grading PPI, as several different 
aspects are considered 82,149. However, there is not yet international consensus regarding 
stratification or grading of urinary incontinence into mild, moderate and severe forms.  
Some authors have proposed ‘severe incontinence’ to be the same as ‘total 
incontinence’ with reported rates of 5% to 10% after RP, increasing with age 150. The 
proportion of patients requiring surgery for PPI following RP is another measure of the 
prevalence of ‘severe PPI’, and the proportion has been reported to be between 5% and 9%, 
but a source of error could be that some patients may never have been offered surgical 
treatment 114,115.  
Urinary incontinence can be divided into different types. Stress urinary incontinence 
(SUI) is the complaint of involuntary leakage on effort or exertion, or on sneezing or 
coughing 143. The symptom of SUI has shown a positive predictive value of 95% and a 
negative predictive value of 100% regarding ISD 136.  
Urgency urinary incontinence (UUI) is the complaint of involuntary leakage 
accompanied by or immediately preceded by urgency 143. The symptom of UUI has shown a 
positive and negative predictive value of 44% and 81%, respectively, regarding DO 136.  
Mixed urinary incontinence is a combination of SUI and UUI. Post-micturition dribble 
describes the involuntary loss of urine immediately after urinating. Nocturnal enuresis is the 
complaint of loss of urine during sleep 143. 
Following RP, other urinary symptoms than incontinence may be present. Additional 
storage symptoms include urinary frequency, nocturia, and urgency. Voiding symptoms 
include slow stream, hesitancy, straining, and terminal dribble. Post-micturition symptoms 
include the feeling of incomplete emptying and post-micturition dribble 143. 
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 Urinary diary and pad weighing test 
Urinary diaries, also known as voiding or bladder diaries, are useful tools when evaluating 
urinary function and urinary incontinence. ICS has defined the following three types of 
urinary diaries on the basis of the recorded parameters 143: 
1. Micturition time charts record only the times of micturition, day and night, for at least 
24 hours. 
2. Frequency-volume charts record the volumes voided and the time of each micturition, 
day and night, for at least 24 hours. 
3. Bladder diaries record the times of micturition and voided volumes, as well as other 
information, such as incontinence episodes, pad usage, fluid intake, degree of urgency, 
the degree of incontinence, and precipitating activities. 
Urinary diaries have been commonly used and recommended in the assessment of patients 
with lower urinary tract symptoms. Many patients have poor insight into their voiding habits, 
and a bladder diary provides the most objective, reliable, and reproducible means to analyze 
the historical aspects of the incontinence; elucidating the frequency and volume of voids, 
functional bladder capacity, and the activities that cause urinary incontinence – the latter 
being an important factor in determining the treatment choice. Recently Bright et al. 
developed and validated a urinary diary for the first time 151. 
The grade of the urinary leakage can be objectively quantified by a standardised pad 
weight test as recommended by the ICS 143. The 24-hour pad test is the most accurate, 
objective and reproducible test for quantification of incontinence 115,152-154. The test has 
excellent correlation with the subjective patient assessment of the degree of incontinence and 
is the most widely used 153. However, a graded severity scale based on the 24-hour pad test 
has not yet been established for men.  
 - 36 -
 Urodynamics
The term ‘urodynamics’ encompasses any investigation of lower urinary tract dysfunction 
from the simple to the sophisticated, and include voiding diary and pad testing, as mentioned 
above, free uroflowmetry and ultrasound for post-void residual urine estimation, and invasive 
urodynamics 155. However, generally the term ‘urodynamics’ has become synonymous with 
invasive urodynamics. All definitions below are obtained from the ICS reports and associated 
documents 134,143,145,156-158. 
The aim of clinical urodynamics is to reproduce symptoms while making precise 
measurements in order to identify the underlying causes for the symptoms, and to quantify the 
related pathophysiologic processes 158. In that way it is possible to guide treatment correctly 
in relation to the patients’ symptoms. Bladder dysfunction may be demonstrated with 
urodynamic investigation even in the absence of signs and symptoms reported by the patients. 
Thus, urodynamics represent the only method to accurately diagnose causes of incontinence 
and any other dysfunction during the storage or voiding phases.  
 Urodynamics may be divided into non-invasive urodynamics (catheter-free 
uroflowmetry) and invasive urodynamics (filling cystometry and pressure-flow study of 
voiding).  
Free uroflowmetry is a simple and non-invasive way of understanding both storage and 
voiding symptoms. Estimation of post-void residual urine by ultrasound completes the non-
invasive assessment of voiding function. Documentation of a maximum urinary flow rate 
(Qmax), voided volume, duration of voiding and the shape of the flow curve during a 
representative flow as well as the post-void residual give useful information. 
- Bladder voiding efficiency (BVE) is a product of bladder contractility against urethral 
resistance and is measured according to the degree of bladder emptying:  
BVE = (voided volume/total bladder capacity) x 100 
There is no defined pathological cut-off, although no post-void residual urine 
and a BVE of 100% is normal. 
However, a reduced flow rate on the uroflowmetry cannot distinguish between obstruction 
and poor detrusor contractility. As the voiding function reflects the interaction between the 
relaxed outlet and the contracting detrusor, variation of both will affect the flow 158.  
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 Invasive urodynamics consists of two parts: the filling cystometry (simulating and 
measuring the filling phase) and the pressure-flow study (simulating and measuring the 
voiding phase) 158. During filling cystometry, the bladder is filled with isotonic saline, usually 
in the rate of 20-60 ml/min, simulating the physiologic filling of the bladder. Physiologic 
filling rate is defined by the ICS as body weight (kg) divided by four, expressed as ml/min 
(for example 80/4=20 ml/min). Bladder sensations are recorded and evaluated as normal or 
not. Detrusor overactivity (DO) and reduced compliance may be observed, in contrast to a 
normal filling phase with stable detrusor pressure (little or no change). Incontinence related to 
DO or related to increased abdominal pressure may be observed during filling cystometry 158.  
- Detrusor overactivity (DO) is a urodynamic observation characterized by involuntary 
detrusor contractions during the filling phase 143.  
- Bladder compliance(C) describes the relationship between change in the bladder 
volume (ǻV) and change in detrusor pressure (ǻPdet) 143:  
C = ǻV / ǻPdet 
C 20 ml/cmH2O is defined as impaired/poor compliance. 
- Detrusor overactivity incontinence is defined as urgency incontinence because of an 
involuntary detrusor contraction 143.  
- Urodynamic stress incontinence is defined as an involuntary leakage of urine during 
increased abdominal pressure in the absence of a detrusor contraction 143.  
- The abdominal or Valsalva leak point pressure (ALPP/VLPP) is defined as the 
intravesical pressure at which urine leakage occurs due to increased abdominal pressure in 
the absence of a detrusor contraction 143. The ALPP can be useful in the assessment of 
degree of ISD and when considering treatment choices for SUI 159. According to Abrams 
an ALPP 60 cmH2O implies intrinsic sphincter deficiency (ISD) 134. However, there are 
several problems related to the measurement of ALPP, regarding patient compliance and 
position, bladder volume, the indwelling catheter, moment of measurement etc 115. 
Therefore, that parameter has limited value in the clinical setting.  
- The maximum urethral closure pressure (MUCP) can be assessed by urethral pressure 
profilometry during filling cystometry and is an assessment of urethral function. The 
MUCP is defined as the maximum difference between the urethral pressure and the 
intravesical pressure 143. The urethral pressure is the fluid pressure needed to just open a 
closed urethra 143. According to Abrams an MUCP 20 cmH2O is equivalent to an 
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 ALPP 60 cmH2O, implying ISD 134. However, there are also problems with the MUCP 
as there is a large overlap with normal continent people. Urethral pressure profilometry 
alone is not satisfactory for the diagnosis of urodynamic stress incontinence 160. 
 
In the pressure-flow study, voiding is assessed by measuring urine flow rate and voiding 
pressures, and studying their relationship 156,158. Nomograms, including the quite similar 
Abrams-Griffiths nomogram, the Schäfer nomogram and the most recent ICS nomogram, can 
be used to categorize patients’ bladder contractility and outlet 156.  
- Detrusor underactivity is defined as a contraction of reduced strength and/or duration 
causing slow or incomplete emptying of the bladder 143. One way of measuring detrusor 
contractility is by the bladder contractility index, BCI 156.  
BCI = Pdet@Qmax + 5 x Qmax  
where Pdet@Qmax is the maximum detrusor pressure at  maximum flow rate 
(Qmax). BCI <100 indicates weak contractility. 
- Bladder outlet obstruction is characterised by increased detrusor pressure and reduced 
urine flow rate 143. The bladder outlet obstruction index, BOOI, is calculated as 
follows 156: 
BOOI = Pdet@Qmax – 2 x Qmax 
BOOI > 40 is obstructed, 20-40 is equivocal, and < 20 is unobstructed  
The abovementioned nomograms and indices, BCI and BOOI, were originally validated for 
men with an enlarged prostate, and have not been validated in men without a prostate. After 
RP the urethra offers little resistance to micturition, thus low detrusor pressures are sufficient 
for a normal urinary flow rate 161. Thus, the standard urodynamic classifications in 
nomograms and by indices may be misleading in prostatectomized men. However, they are 
frequently used in lack of something better 137. 
 
Urodynamic studies after radical prostatectomy 
Few studies have compared urodynamic findings before and after RP 5,137,137. The review by 
Porena et al. (2007) presented nine prospective studies comparing preoperative and 
postoperative urodynamic data (Table 3) 137. Results on bladder dysfunction after RP varied 
widely and the role of RP in the development of bladder dysfunction was controversial 137. In 
most prospective studies DO was associated with other urodynamic dysfunctions.  
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  ISD was by far the most common finding in men undergoing urodynamics for 
PPI 136,137,161. Coexisting urodynamic bladder dysfunction (reduced bladder compliance, 
detrusor overactivity, impaired detrusor contractility) was present in 9% - 88% of the patients 
after RP 137. Urodynamic bladder dysfunction was presented as the sole diagnosis in 0% to 
100%, with DO in 0% to 40%, while ISD was presented as sole diagnosis in 2% to 71%. 
Impaired detrusor contractility (26%-33%) and reduced bladder compliance (1%-59%) have 
traditionally been thought to resolve within 8 months after RP 137. 
 
 
 Table 3. Characteristics of the studies and bladder dysfunctions after RRP 137 
Authors, year 
Type 
of 
study 
No. of 
patients 
Follow-
up DO RBC 
Impaired 
detrusor 
contractility
BOO SUI 
SUI and 
bladder 
dysfunction
Hellstrom et al, 1989 P 19a 6 —  19 (100) — — — 
Presti et al, 1990 R 24b 60 6 (25)c — — — — — 
Foote et al, 1991 R 71 40 0 (0) 5 (7) — — 25 (35) 29 (41) 
Foote et al, 1991 P 26 12 — — — — 8 (33) 17 (67) 
Constantinou and 
Freiha, 1992 P 13 23 8 (62)
d — — — 0 — 
Leach and Yun, 1992 R 71 12 0 (0) 8 (12) — — 26 (37) 22 (31) 
Goluboff et al, 1995 R 25 37 10 (40) 2 (8) — — 2 (8) 13 (52) 
Sasaki et al, 1995 P 25 12 — 5 (20) — — — — 
Leach et al, 1996 R 25e 36 1 (4) 3 (12) — — 8 (32) 12 (48) 
Minervini et al, 1996 P 39 6 12 (31)c — — — — — 
Hammerer and 
Huland. 1997 P 82 6 33 (41)
c — — — — — 
Ficazzola and Nitti, 
1998 R 60 13 5 (8) 0 — 5 (8)
f 32 (53) 22 (37) 
Winters et al, 1998 R 65 59 1 (1.5) — — — 46 (71) 18 (28) 
Kleinhans et al, 1999 P 44 7.6 3 (6.8) — — — 1 (2.3) 0 (0) 
Groutz et al, 2000 R 83 32 3 (4) — 1 (1.2) 1 (1.2) 26 (32) 73 (88) 
Giannantoni et al, 
2004 P 49 8 — — — — — 32 (65) 
Huckabay et al, 2005 Pg 60 32 24 (40)c — — 8 (13) 35 (58) 25 (42) 
Kielb and Clemens, 
2005 R 146 49 1 (0.7) 14 (10) 48 (33) 19 (13) 95 (65) 44 (30) 
Majoros et al, 2006 P 63 2 11 (17) 1 (1.6) 2 (3) 3 (5) 38 (60) 6 (9) 
Data are shown as number of patients, number of months, or n (%).  
RRP=retropubic radical prostatectomy; DO=detrusor overactivity; RBC=reduced bladder compliance; BOO=bladder 
outlet obstruction; SUI=stress urinary incontinence; R=retrospective study; P=prospective study; — =not reported. 
a Seven patients had a previous transurethral resection of the prostate (TURP). b Four of 24 incontinent patients and 1 
of 13 continent patients previously underwent TURP; 1 of 24 incontinent patients previously underwent radiotherapy 
and hormonal therapy. c The authors did not specify if DO was associated with other dysfunctions. d Seventy-eight 
percent of patients were overactive before surgery. e Twenty-four patients had RRP, and 1 had perineal 
prostatectomy. f Three of 5 patients complained of DO. g Without preoperative urodynamics.  
Copyright has been obtained. 
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 Later, Giannantoni et al. (2008) compared urodynamic status in 54 patients before and 
after RP. They found DO in 61% of patients before RP and 70% eight months after RP 
(p>0.05), which indicated that surgery may be the cause of DO in a small percentage of 
patients (9%). Among the patients with normal detrusor function preoperatively 30% had 
weak detrusor contractility postoperatively. Regarding abnormalities directly related to the 
long-term consequences of an obstructing prostate before RP, the presence of bladder outlet 
obstruction (BOO) decreased from 59% before RP to 7% after RP (p<0.001), and 
DO together with BOO decreased from 35% to 3% (p<0.001). The presence of DO and weak 
detrusor contractility together increased from 17% to 39% (p=0.05). ISD was not found in 
anyone before RP and in 74% after RP (p<0.001).  
Among the 32 patients followed for 36 months after RP, 56% had DO, de novo in 
16%. Impaired bladder compliance was present in 28%, de novo in 16%, and weak detrusor 
contractility in 25%, de novo in all. ISD was present in 59%, de novo in all. 
In that study detrusor contractility was evaluated by the Schäfer nomogram, which 
may overestimate hypocontractility in a prostatectomized population, as mentioned above. 
Nevertheless, a high proportion of patients had long-term urodynamic abnormalities 
following RP, including both dysfunctions that developed de novo and that also had been 
present preoperatively. 
In conclusion, there are a few good studies comparing urodynamics before and after 
RP, mostly showing that several dysfunctions are often present simultaneously. However, due 
to diverging results in these studies it is hard to conclude on the pathogenesis of the bladder 
dysfunctions, whether the factors are pre-existing or develop de novo following surgery. 
 
Urodynamic studies before incontinence surgery 
Urodynamic investigation is recommended in the evaluation of PPI, especially prior to 
surgical treatment 67,115,115,157,162-164. This recommendation is not evidence-based 
however 165,166. Previous studies, although few, have not been able to show that urodynamics 
can predict outcome of PPI surgery 167-169.  
Bladder dysfunctions, especially detrusor overactivity and underactivity, have 
traditionally caused some concern when planning PPI surgery. The hypothesis has been that 
detrusor overactivity may potentially be aggravated with partial obstruction caused by an 
artificial urinary sphincter (AUS) or a sling, while detrusor underactivity may lead to 
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 incomplete bladder emptying in such a situation. However, no studies have been able to 
confirm that. Thiel et al. retrospectively studied 86 patients with AUS for PPI 168. The 
presence of detrusor overactivity or reduced bladder compliance in patients before PPI 
surgery did not predict AUS failure (>1 pad/day). In a prospective study of 40 patients after 
RP, Trigo-Rocha et al. did not find significant associations between urodynamic bladder 
dysfunctions (detrusor overactivity, impaired detrusor contractility, reduced bladder 
compliance) and worse surgical outcome (>1 pad/day) 169. Gomha and Boone, however, 
found in a study of 86 patients that poor bladder compliance was associated with persistent 
urgency and urgency incontinence after AUS implantation 170. 
Only patients with AUS implantations, not slings, had been studied in this respect. 
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 1.3.5. Treatment of postprostatectomy incontinence 
 
 
 
Figure 6. Initial and specialized management of PPI based on EAU 2010 guidelines 67 
Copyright has been obtained. 
 
Overview
Contemporary management of PPI is summarized well by Bauer et al. (Figure 6) 67. They 
advocate an initial two-step assessment. The first concerns evaluation of symptoms, urine 
analysis, residual urine, QOL, grade (amount) of stress incontinence and assessment of pelvic 
floor muscle function. In a second step, it is recommended that all patients then undergo 
pelvic floor muscle training, lifestyle intervention and bladder training. Those with urgency 
urinary incontinence (UUI) should be treated with anticholinergic medication, 
Į1-adrenoceptor blockers, or a combination 171. Some of those with mild stress urinary 
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 incontinence (SUI) who are reluctant to undergo surgical treatment can theoretically be 
treated with Duloxetine, a serotonin-norepinephrine reuptake inhibitor, although the usage of 
Duloxetine for SUI is off-label and not applied in Norway 171. In those who fail conservative 
treatment, specialized management with endoscopic and urodynamic evaluations are 
recommended. However, there is no definite statement to the effect of such evaluations.  
In patients with persistent SUI, surgical treatment is recommended after initial 
conservative therapy has failed or is insufficient 67,115. Well-established surgical treatment 
options for PPI include urethral slings and the artificial urinary sphincter (AUS). A common 
view is that patient’s demands for minimally invasive treatment options are high and will 
drive the choice to use a sling to avoid using a mechanical device such as the well-established 
AUS 67. Other options include urethral bulking agents and the adjustable balloon system, both 
of which have not shown as promising results as the AUS and the slings, and are not 
primarily recommended for PPI 67,67,115,157. Transurethral injection of autologous muscle stem 
cells to reconstitute the deficient urethral sphincter has been introduced but the efficacy has 
yet to be established 172. 
Surgical interventions after failed conservative therapy for DO include intradetrusor 
injection of Botulinum Toxin A, sacral nerve stimulation/modulation, and 
enterocystoplasty/urinary diversion 162. These topics will not be covered in this thesis. 
The most recently published ‘EAU Guidelines on Surgical Treatment of Urinary 
Incontinence’ (2012 and Update in 2014) have based their recommendations on three recent 
literature reviews on the subject by Herschorn et al., Abrams et al., and Bauer et. al 67,115,157. 
Their recommendations are summarized below 162: 
 
Urethral slings 
There are two types of male urethral slings for SUI available; fixed and adjustable. Fixed 
slings (vide infra) are positioned under the bulbar urethra and introduced and fixed by a 
retropubic or transobturator approach, while the adjustable slings (Remeex®, Argus®, 
ATOMS®) can be adjusted postoperatively. Available evidence indicates that the fixed slings 
seem superior to the adjustable slings 162.  
For the fixed slings, two therapeutic concepts are proposed for continence restoration: 
Urethral compression (InVance®, TOMS®, Argus®) and repositioning of the urethral bulb 
(AdVance®, Figure 7). Published reports indicate that fixed slings cure or improve PPI for at 
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 least three to five years and are less effective for men with severe incontinence (>400g/24h), 
previous RT, or previous urethral stricture therapy 144,172. 
The InVance® is a bone-anchored perineal sling that has been evaluated quite 
extensively with success rates of 40%-88% with follow-up of up to 48 months 115,173. Due to 
high complication rates and low success rates, the sling has been removed from the market in 
some countries 172.  
The AdVance sling (Figure 7) is a retrourethral transobturator sling and has reported 
success rates of 76%-91% with follow-up of 12-36 months 115. The most common adverse 
events reported are urinary retention (3%-21%) and perineal pain (0-20%). Rare adverse 
events include compartment hematoma, worsening of urinary incontinence and urethral 
perforation 115. Despite continued patient satisfaction, it has been shown that patients use an 
increasing number of pads/day as time advance from the sling procedure 174.  
At OUH Rikshospitalet, the AdVance sling was introduced in 2009.  
 
Artificial urinary sphincter 
The artificial urinary sphincter (AUS) AMS800® has been used for the treatment of SUI for 
almost 40 years 175. This device restores continence with an occlusive cuff around the bulbar 
urethra (or the bladder neck) and a corresponding pump (opening switch) that is implanted 
subcutanously in the scrotum (Figure 8). The AMS800® was introduced at OUH 
Rikshospitalet in 1983 and was initially mostly used for treatment of neurogenic SUI, and 
rarely for PPI.  
Although the AMS800® is considered to be the gold standard treatment for men with 
SUI, the level of evidence is low for this statement 162. There have been no well-designed 
randomized controlled trials comparing the abovementioned surgical options for SUI in men. 
Cohort studies suggest that AUS implantation is effective for cure and improvement of SUI in 
men, although long-term device failure is common and patients should be informed that there 
is a high risk of needing revision/replacement after 5-10 years 172. Previous pelvic 
radiotherapy does not appear to affect the outcome of AUS implantation. Tandem-cuff 
placement (two cuffs around urethra) has been tried to improve continence rates, but has not 
been shown to be superior to single-cuff placement. 
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c
 
Figure 7. a) The AdVance ® sling is a retrourethral transobturator sling inserted 
from the perineum by helical introducer needles. b) and c) The postulated mode of 
action is a repositioning of the bulbar part of the urethra into the pelvic floor 176.  
Copyright has been obtained. 
 
 
 
 
 
 
Figure 8. The AMS800® artificial 
urinary sphincter consists of three parts: 
the cuff, the pump, and the reservoir 175.  
Copyright has been obtained. 
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 The proportion of patients who continue to experience treatment success (measured by 
requiring 0-1 pads per day) after implantation of an AUS ranges from 59% to 90%, with 
mean up to 11 years follow-up 115 (Table 4). High satisfaction rates of 87%-90% are reported, 
even without total continence 115.  
 
Table 4. Results of the artificial urinary sphincter in postprostatectomy 
incontinence 115 Copyright has been obtained. 
Author, year No. pts. Follow-up (yrs) 0-1 pad/day 
Goldwasser et al., 1987 42 1.2 82% 
Montague, 1992 66 3.2 75% 
Perez and Webster, 1992 49 3.7 85% 
Martins and Boyd, 1995 28 2 85% 
Fleshner and Herschorn, 1996 30 3 87% 
Haab et al, 1997 36 7.2 80% 
Klijn et al., 1998 27 3 81% 
Mottet et al., 1998 96 1 86% 
Madjar et al., 2000 71 7.7 59% 
Lai et al., 2007 218 3.1 69% 
Trigo-Rocha et al., 2008 40 4.5 90% 
Kim et al., 2008 124 6.8 82% 
 
 
Three papers had reported QOL after implantation of AUS for PPI. At a mean of 39 
months follow-up, Fleshner and Herschorn observed similar QOL in patients operated on 
with AUS as reported by patients without PPI 177. Haab et al. found that after a mean follow-
up of 7.2 years, 43 of 54 patients treated with an AUS reported good QOL 178. Hussain et al. 
reported significant improvement of QOL in 34 men at a median of 24 months after AUS 
implantation 175. However, in these studies, QOL was related to urological problems only, 
focusing on the patients’ well-being related to urinary symptoms affecting daily activities, 
so-called incontinence-related or disease-specific QOL 179. No studies regarding generic QOL 
after surgical treatment of PPI were identified. 
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 A newly introduced AUS, the FlowSecure®, has a different design than the 
AMS800®, with an adjustable balloon capacity through a self-sealing port. Its effectiveness is 
not yet established. AUS implants with other designs are under ongoing development and 
evaluation 172. 
Following recurrent incontinence after AUS implantation, there are several treatment 
options, depending on reason for failure. Incontinence can result from alteration in bladder 
function, atrophy of the urethra, mechanical failure of the device, or erosion/ infection 180. 
Urethral atrophy may occur at the cuff site secondary to long-term mechanical compression. 
Treatment options consist of decreasing the cuff size, increasing the balloon pressure, 
implanting a double-cuff system, or proximal cuff repositioning. Regardless of the reason for 
mechanical failure, the relevant part of the AUS must be replaced. Erosion and/or infection 
are two major complications that almost always necessitate removal of the complete 
device 180. 
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 1.4. Summary and reasons for doing this thesis 
 
The high incidence of PCa and increasing use of RP as curative treatment leads to an 
increasing prevalence of PPI, in both younger middle-aged working men and older retired 
men. In Norway, patients have a basic right to have AEs evaluated and treated if indicated 181. 
For a long time, PPI was neglected and represented a very little burden for the health care 
system in Norway. Information to patients and general practitioners about treatment of PPI 
was scarce and not highly prioritized by urologists. Until 2012, based on a national agreement, 
OUH Rikshospitalet was the only department in Norway offering surgical treatment of PPI, 
treating patients from the whole country. From the 1980’s to 2006 there were between two 
and nine operations for PPI per year, with a 50-100% increase annually thereafter (18 in 2007, 
74 in 2011), a trend similar to other countries 182. Since 2012, a few more urological 
departments offer PPI surgery as the increasing demand was difficult to handle in one 
department only.  
At that time (2007-2012) I worked as a resident in urology at Rikshospitalet and 
witnessed this development. I got to know these patients who were in despair because they 
were among “the unlucky 1%-2%” who experienced the PPI after RP. Their perception was 
very often that the prevalence of PPI should be very low.   
 I observed that there was a lack of research in Norway, and in Scandinavia in fact, 
regarding the true prevalence of PPI after RP, the pathophysiology and characteristics of 
severe PPI, as well as the outcome of PPI surgery, including QOL. Access to relevant local 
information is necessary to be able to give patients correct preoperative counselling, both 
before RP and before PPI surgery. “The satisfied patient is one whose outcomes match 
expectations” 147. However, the problem is not present only in Norway as prevalence rates of 
PPI vary widely internationally, and others also report of patients’ unrealistic expectations of 
continence, in spite of sober preoperative counselling 183.  
The head of the Department of Urology at OUH Rikshospitalet, Professor Hans 
Hedlund, supported me when I announced my interest in doing research on PPI and its 
surgical treatment. As he was close to retirement, he arranged the contact with the National 
Advisory Unit on Late effects after Cancer Treatment, which became my workplace while 
doing this thesis. As a supervisor he also stimulated my work together with my two 
supervisors at the Unit, Professor Sophie D. Fosså, and Professor Alv A. Dahl.  
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 2. THIS THESIS 
 
2.1. Introduction 
 
The work presented in this thesis began in 2010. At that time, increasing referral of patients 
with PPI to the Department of Urology at OUH Rikshospitalet was obvious with a 
considerable waiting list. The artificial urinary sphincter AMS800® was being increasingly 
used in these patients, and new surgical methods emerged, including the ProACT® and the 
AdVance® sling. However, none of these methods or their postoperative outcome had been 
evaluated at the Department. 
 At the same time two prospective studies of patients self-reporting AEs after curative 
treatment of PCa had been started at the Departments of Urology and Oncology at OUH 
Radiumhospitalet. Patients who had undergone RP there from 2005 to 2007 were included in 
a local study (the OUH study) and patients who had undergone RP at 14 of a total of 17 
urological units in Norway in 2008 and 2009 were included in a national study (the NUCG 
VII study).  
I was invited to take part in these studies to explore several aspects of PPI, such as 
identification of prevalence, predictors, urodynamic findings, and outcome of surgical 
treatment (Articles I and II). At the same time, at Rikshospitalet we started with a cross-
sectional study of the outcome and QOL of the patients operated there for PPI between 2002 
and 2010 (Article III). 
 Based on the Background and these opportunities at OUH, the current thesis was 
motivated by the following study aims: 
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 2.2. Study aims 
 
The current thesis comprises three sub-studies represented by Papers I-III.  
 
Paper I: How should continence and incontinence after radical prostatectomy be 
evaluated? A prospective study of patient-ratings and changes over time 
 
Background:  
There is no international consensus on the optimal way to define, assess and grade PPI, which 
partially explains the wide range of prevalence rates reported, from 1% to 87%. Ellison et al. 
(2013) recently proposed a grading system for urinary incontinence based on the EPIC-26 
into no/mild, moderate and severe incontinence.  
Aims: 
1) To examine how different definitions impact on the prevalence of patient-reported 
continence and incontinence at baseline and 12 months after RP, and analyzing changes.  
2) To determine the descriptive validity of the PPI grading system proposed by Ellison et al. 
3) To study baseline (pre- and peroperative) predictors of PPI at one year after RP. 
Hypothesis: 
Our hypothesis was that different methods of evaluating PPI would result in a wide difference 
of prevalence rates, and that the descriptive validity of the PPI grading system of Ellison et al. 
would be acceptable. 
 
Paper II: Severe postprostatectomy incontinence: Is there a significant association 
between preoperative urodynamic findings and outcome of incontinence surgery? 
 
Background:  
There is little evidence for urodynamic investigation prior to surgical treatment of PPI, but it 
is recommended nevertheless. Bladder dysfunctions could theoretically compromise outcome 
of PPI surgery. We therefore wanted to study whether there were any associations between 
preoperative urodynamic findings and outcome of incontinence surgery in patients with 
severe PPI. 
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 Aims: 
1) To describe the results of the clinical urological examination of patients with severe PPI. 
2) To collect patient-reported outcome of PPI surgery. 
3) To study the associations between preoperative urodynamic findings and the outcome of 
PPI surgery. 
Hypothesis: 
Our hypothesis was that the presence of urodynamic bladder dysfunction preoperatively 
would predict an unsuccessful outcome after PPI surgery, defined as dissatisfaction or use of 
more than one pad/day. 
 
Paper III: Study of generic quality of life in patients operated on for postprostatectomy 
incontinence. 
 
Background:  
Many patients complain of persistent PPI, which is associated with reduced quality of life 
(QOL). Reported postoperative continence rates after implantation of an artificial urinary 
sphincter (AUS) are high but the impact of this treatment on generic QOL is not well 
documented. 
Aims:  
1) To identify the rate of patients with poor generic QOL after implantation of an AUS for 
PPI (cases) and to compare this rate with that observed in men from the general population 
(controls). 
2) To compare patients with poor generic QOL with those who report better QOL as to 
sociodemographic, cancer-related, surgical, urinary and sexual problems, mental distress, and 
patient satisfaction variables. 
3) To identify the independent variables significantly associated with poor generic QOL. 
Hypothesis: 
Our hypothesis was that persistent urinary incontinence problems, rather than psychosocial 
variables, would be most strongly associated with poor generic QOL in such patients. 
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 2.3. Patient sampling 
 
Papers I and II (Figure 9) 
The study sample for papers I and II derived from two prospective studies of AEs after RP for 
localized PCa, including 1) the local ‘OUH study’ of 156 patients treated between 2005 and 
2007 105, and 2) the national ‘NUCG VII study’ of 688 patients treated at a total of 14 
urological units in Norway between 2008 and 2009 184. Both studies were initiated and 
analyzed at OUH. 
Of the total of 844 included patients, 735 patients (87%) had completed all urinary 
incontinence items of the EPIC-50 or the UCLA-PCI, equivalent to the four items of the 
urinary incontinence domain (UID) of the EPIC-26, immediately before RP and 12 months 
postoperatively. Those patients were the basis for paper I. 
 In order to identify patients with persistent severe PPI in that sample, a new 
questionnaire (Q1) was sent out more than 12 months postoperatively (February 2011). The 
94 patients who reported ‘severe PPI’ (defined below) were invited to a clinical examination 
and 76 patients (81%) attended. Fifty-three patients were subsequently referred for PPI 
surgery and by January 2014 46 patients had been operated with either an AUS or a sling. 
Two patients had died and were excluded from the second part of this study, leaving 44 
patients evaluable postoperatively. They received a mailed follow-up questionnaire in January 
2014 and 43 (98%) replied. The examined (N=76) and the operated patients (N=43) served as 
a basis for paper II (Figure 10). 
Attrition analysis of the 109 patients who did not complete the baseline and 12-month 
questionnaires showed no significant differences from those who completed the 
questionnaires regarding baseline variables like sociodemographics, comorbidity, PCa stage 
and risk groups, and treatment approach and nerve sparing technique.  
Attrition analysis of the 18 patients who declined clinical examination showed that 
they had higher mean UID score on the Q1 questionnaire (24 vs. 17, p=0.01) before PPI 
surgery, i.e. they had less PPI, when compared with those 76 patients who attended the 
clinical examination. Otherwise no significant differences were observed. 
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RP 2005-2009 (N=844)
Questionnaires preoperatively and 12 months postoperatively
No reply (N=109)Questionnaire Q1 Febr. 2011
Completed PPI questionnaire (N=533)
No LUTS, excluded (N=93)
Severe PPI (N=94)
Not severe PPI, excluded (N=439)
Clinical examination 2011-2012 (N=76)
Declined examination (N=18)
Completed questionnaires at baseline and 12 months (N=735)
LUTS at 12 months (N=642)
Referred to PPI surgery (N=53)
Not referred to PPI surgery (N=23)
Not evaluable (N=10)
Evaluable after PPI surgery (N=43)
No reply or incomplete questionnaires (N=109)
Questionnaire Q2 Jan. 2014
 
 
Figure 9. Patient flow diagram for papers I (first part of the diagram, N=735) 
and II (second part of the diagram, N=76) 
Abbreviations: RP: Radical prostatectomy. LUTS: Lower urinary tract symptoms (including incontinence).  
PPI: Postprostatectomy incontinence.  Questionnaire Q1: before PPI surgery, and Q2: after PPI surgery. 
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 Paper III 
Between January 2002 and June 2010, 107 patients had an AUS implanted for PPI at the 
Department of Urology, OUH Rikshospitalet. By January 2011, five patients had died and the 
AUS was removed in two patients. The remaining 100 patients were invited by mail to 
complete a follow-up questionnaire, and 85 complied.  
Attrition analysis showed that the 15 non-responding patients did not differ 
significantly from the 85 complying patients regarding preoperative features like leakage and 
pad use, age and comorbidity at surgery, follow-up time or postoperative complications after 
PPI surgery. 
 
Normative data and control group 
For paper III a sample of men from the general population served as controls for the cases. 
The Survey of Living Conditions 2002 by Statistics Norway 185 included a questionnaire with 
the Short Form-36 QOL instrument to a representative sample of the Norwegian population 
aged 15 years and older (n = 6827, among which 3410 were males). The SF-36 was 
completed by 2514 males (76% response rate), among which 623 males were in the age range 
of our cases. We retrieved the shortened SF-12 QOL scorings of these men, and registered 
their level of education, paired relationship and work status. These data served as controls for 
the cases. 
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 2.4. Methods 
 
The methods behind this thesis are primarily based on questionnaires (Papers I-III) and 
secondarily based on the clinical evaluation of patients with severe PPI (Paper II).  
Paper I was based on a prospective study of self-reported AEs after RP. The patients 
rated themselves at baseline (before RP) and at 12 months following RP, with either the 
UCLA-PCI or the EPIC-50. Paper II also reports a prospective study, a follow-up of the first 
study, where the patients received an additional questionnaire (Q1) more than 12 months after 
RP, to identify more definitely those with persistent severe PPI. These patients were then 
invited to a clinical examination including urodynamics, operated for PPI when indicated, and 
re-evaluated with questionnaire postoperatively (Q2). Paper III was a cross-sectional 
questionnaire-based study of self-reported outcome and QOL after PPI surgery.  
PCa related variables (PSA at diagnosis, Gleason score of biopsies, clinical and 
pathological T stage, and positive surgical margins), surgery related variables (RP surgical 
approach [RRP vs. RARP], nerve sparing technique) (Paper I), preoperative features and 
postoperative events (Papers II and III) were retrieved from the Norwegian Prostate Cancer 
Registry and the patients’ medical records, respectively. The risk group classification of 
D’Amico et al. was applied 43. Current hormone therapy, previous pelvic radiotherapy, and 
relapse of PCa were self-reported. 
The questionnaires, the clinical examination, the surgical methods, and statistical 
analyses are described below. 
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 2.4.1. Questionnaires 
Assessment of adverse effects: UCLA-PCI, EPIC-50 and EPIC-26 
In this thesis, Norwegian versions of the UCLA-PCI, the EPIC-50 (Paper I) and the EPIC-26 
questionnaires (Papers II, III) were used for rating AEs before and after RP.  
The UCLA-PCI was specifically developed to assess typical AEs after treatment for 
PCa 82. The EPIC-50 is a modified and extended version of the UCLA-PCI and includes 
additional items to capture concerns relevant to RP, RT, and androgen deprivation 95. The 
EPIC-26 is an abbreviated version of the EPIC-50 96.  
The EPIC questionnaires cover the experience of urinary, sexual, bowel, and 
hormonal functions, and bother (problems) related to each function, and overall problems. 
Response options for each item form a 4- to 5-point Likert scale, and the scores are converted 
to a 0 – 100 scale with higher scores representing better function and less bother/problem 186. 
Multi-item domain scores are the mean of the item scores of each domain (domain sum score 
divided on the number of items).  
All three instruments have four identical items comprising the urinary incontinence 
domain (UID). However, other items of the three instruments have been developed and 
changed over time; hence for example the items of the urinary obstructive/irritative domain 
(IRR) are not identical across instruments. The complete urinary domain of the most recent 
and recommended instrument, the EPIC-26, comprises nine items; the UID and the IRR with 
four items each, and one item addressing overall urinary problem (see Appendix).  
Ellison et al. (2013) stratified PPI using the UID score of the EPIC-26, classifying a 
score of 0 – 49 as severe, 50 – 69 as moderate and 70 – 100 as mild/no PPI. This stratification 
was studied in our sample in Paper I 187. For Paper II, severe PPI was defined as UID score 
<35 more than 12 months after RP (EPIC-26) corresponding to the 80th percentile of the UID 
scores on Q1, and those patients were invited to a clinical examination (Figure 9).  
The sexual domain of the questionnaires was used in Papers I and III, but the 
hormonal and bowel domains were omitted from analysis (Paper III) or not used at all (Papers 
I and II) because of little relevance to RP patients. 
 
Satisfaction with surgery 
The patients’ general satisfaction with surgery (both PCa and incontinence surgery) can be 
rated by one question on a 5-point Likert scale. Specific satisfaction with the outcome of 
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 incontinence surgery was covered by five questions similar to those used by Litwiller et al. 
and Gousse et al. 188,189. These questions were used in Papers II and III.  
 
Other questionnaires: SF-12, HADS, EPQ, and WAI 
There are some other psychosocial issues that are important to study in relation to AEs 
following PCa treatment, like generic QOL, anxiety, depression, basic personality traits (like 
neuroticism) and work ability. These topics were studied in Paper III. 
 
Quality of life: SF-12 
The SF-12 rates generic QOL and is an abridged version of the SF-36. The instrument 
consists of 12 items, with one or two items from each of eight health domains: physical 
functioning, physical role functioning, bodily pain, general health perceptions, vitality, social 
role functioning, emotional role functioning, and mental health. Responses are transformed 
into a 0-100 scale with higher score representing better QOL. Physical and mental QOL are 
expressed by the physical composite summary (PCS) and the mental composite summary 
(MCS) scores 102. Based on T-transformation of the raw scores, the mean PCS and MCS 
scores in the Norwegian male population is 50 points and standard deviation 10 190. Mean 
scores above 50 represent better QOL and below 50 worse QOL compared to the general 
population 102.  
 
The Hospital Anxiety and Depression Scale (HADS) 
The HADS is commonly used to determine the levels of anxiety and depression that a person 
has experienced during the last week. The instrument consists of seven items on both the 
anxiety and the depression subscales. The subscale scores range from 0 (low) to 21 (high), 
with higher scores indicating more anxiety or depression 191. Internal consistency in our 
sample was Cronbach’s coefficient alpha 0.82 for depression and 0.83 for anxiety (Paper III). 
 
Neuroticism: The Eysenck Personality Questionnaire (EPQ)  
The EPQ short version assesses three basic personality traits including neuroticism. 
Neuroticism indicates the degree of nervousness and negative emotions from safe and 
positive to anxious and negative, which is important for the experience of disease and 
AEs 192-194. An abridged version of the EPQ, with six items, is developed to assess 
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 neuroticism only (EPQ-N) 195. Each item is rated with yes (1) or no (0), giving a range from 
0 (low) to 6 (high). Internal consistency in our sample was Cronbach’s coefficient alpha 0.72 
(Paper III). 
 
The Work Ability Index (WAI) 
The WAI is a validated instrument used in clinical occupational health and research to assess 
work ability during health examinations and workplace surveys 196,196,197. There is one item 
rating current work ability (WA) that can be extracted from the WAI instrument and used on 
its own. Current WA compared with lifetime best is rated on an 11-point scale from 0 
(completely unable to work) to 10 (WA at its best) and is also relevant for retired men.  
 
Definitions of main outcomes 
Continence categories 
For Paper I, incontinence was reported according to several different definitions. Based on the 
EPIC-26 items urinary control and use of pads the sample was divided into three continence 
categories described by Herschorn et al. for ICS, including 1) total control and 
no pad use (perfect continence), 2) occasional dribbling without pad use and 3) daily pad use 
(the last category being inverted, defining incontinence instead of continence, to include all 
patients in either of the groups) 115.  
In our study, preoperative continence was defined as abovementioned category 1 and 
incontinence included categories 2 and 3. Any category change from baseline to 12 months 
was defined as positive (better) or negative (worse). This categorization was compared with 
the continuous UID score. A UID score change of greater than ±10 on the scale of 0 to 100 
scale was defined as a change (better/worse) 90,91.  
In addition, Ellison et al.’s stratification of no/mild, moderate and severe PPI was 
studied when applied to our sample 187. Category changes according to this stratification from 
baseline to 12 months were studied and compared to the abovementioned changes in 
categorical continence status. That comparison was done although we were aware that the 
two categorizations are not directly comparable since the latter lacks discrimination on the 
severe end.  
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 Outcome after PPI surgery 
In Paper II, successful outcome after PPI surgery (on the Q2 questionnaire) was defined in 
two ways: satisfaction with the operative result and use of 1 pad/day (‘surgical success’). 
Satisfaction was dichotomized into ‘very satisfied’ or ’satisfied’ (‘satisfied patients’) and 
‘uncertain’ or ‘dissatisfied’ (‘dissatisfied patients’) with the PPI surgery. When comparing 
responses before surgery (Q1) with after surgery (Q2), change was defined as a difference on 
the response scale of at least one step for each item. 
 
QOL as outcome 
For Paper III, ‘poor QOL’ was defined as a score <40 on either PCS or MCS of the SF-12, 
and patients with higher scores belonged to the ‘better QOL group’. 
 
2.4.2. Clinical evaluation including urodynamics 
Patients with severe PPI were evaluated with detailed history, physical examination, free 
uroflowmetry with measurement of post-void residual urine, invasive urodynamics and 
cystoscopy. Prior to their clinical visit they had performed three 24-hour pad tests and urinary 
diaries.  
Number of pads and the amount of urinary leakage were noted based on the 24-hour 
pad tests. From the urinary diaries the micturition volumes (smallest, largest, mean, 24h-total) 
and frequency (number of micturitions per 24h) were recorded. 
Prior to urodynamics, non-invasive catheter free uroflowmetry was performed and 
post-void residual urine was measured by catheterization. Bladder voiding efficiency (BVE) 
was calculated 156.  
Urodynamic examination was conducted according to the standards of the ICS 158. The 
standard multichannel cystometry was followed by pressure-flow study. A Ch 8 transurethral 
catheter measured vesical pressure and a rectal balloon catheter the total abdominal pressure, 
and subtracted detrusor pressure (Pdet) was calculated. Filling rate was 20 ml/min (within 
physiologic range).  
Standard terminology regarding bladder and outlet dysfunction was applied 143,156,198. 
Detrusor overactivity (DO) was defined as any involuntary detrusor contraction during the 
filling phase. Bladder compliance (C) > 20 ml/cmH2O was considered normal, 10 – 20 
impaired, and < 10 poor.  
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 At capacity (the subjective feeling of a full bladder) the patient voluntarily voided and 
pressure-flow analysis was performed. Bladder outlet obstruction and bladder contractility 
were based on the ICS nomogram, and bladder outlet obstruction index (BOOI) and bladder 
contractility index (BCI), respectively.  
For the purpose of Paper II some of the abovementioned indices were dichotomized, 
with normal cut-off values of BVE>80%, C>20 ml/cmH2O and BCI100. BOOI <20 was 
considered unobstructed, 20-40 equivocal, and >20 obstructed 156 
Urodynamic stress incontinence is noted during filling cystometry and is defined as 
the involuntary leakage of urine during increased abdominal pressure, in the absence of DO 
(ICS definition) 143. As urodynamic diagnosis of intrinsic sphincter deficiency (ISD) has a 
positive predictive value of 95% and a negative predictive value of 100% versus the 
complaint of stress urinary incontinence (SUI) on a clinical level 136, the latter was considered 
to be sufficient and used as a proxy for ISD.  
Cystoscopy was performed with a rigid Ch 17.5 cystoscope with local gel anaesthesia 
and oral prophylactic antibiotics. The external urethral sphincter and bladder neck were 
inspected and any anatomical abnormality noted. All patients were asked to contract the 
sphincter voluntarily under visual inspection. The observations were classified as: obvious 
sphincter lesion, normal sphincter, bladder neck stenosis (surgery indicated, not passable for 
cystoscope Ch 17.5), and ability to contract sphincter (yes/no). 
 
2.4.3. Surgical technique 
PPI surgery was offered to patients with ISD and a significant amount of urinary leakage (>20 
grams/24 hours) causing ‘moderate or big problems’ (item 4, Q1), regardless of urodynamic 
findings. Essentially, a sling was offered to patients with leakage <400 grams/24 hours, and 
an AUS to those with greater leakage volumes, also considering patients’ preferences. 
Symptomatic detrusor overactivity (DO) and previous pelvic radiotherapy were relative 
contraindications to a sling. Bladder neck stenosis was treated before surgery for PPI was 
performed. 
All patients had surgery under general anaesthesia and with broad-spectrum 
prophylactic antibiotics. For the AUS AMS800® the standard perineal approach was used to 
implant a single cuff around the bulbar urethra, and an abdominal incision for placement of 
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 the pressure-regulating balloon and the pump 175. Cuff size was usually 4.5 cm (range 4.0–5.5 
cm), and the pressure-regulating balloon 61-70 cmH2O.  
The retrourethral transobturator slings AdVance® and A.M.I.®ATOMS were 
implanted through a perineal incision utilizing helical introducer needles 199,200. The middle 
part of the AdVance® sling was fixed to the corpus spongiosum with four stitches of non-
resorbable sutures. The port of the ATOMS® was filled peroperatively and additionally on 
postoperative follow-up visits if necessary  
The AUS was activated 4 weeks postoperatively and the sling-patients had their first 
postoperative control with free uroflowmetry and post-void residual urine measurements six 
weeks after surgery. The patients had further follow-up according to individual needs. 
Postoperative events were retrieved from the patients’ medical records. 
 
2.4.4. Statistics 
For all papers 
Descriptive statistics included mean and standard deviation (SD) for continuous variables of 
normal distribution, median and range in case of skewed distributions, and proportions for 
categorical ones. Groups were compared with independent t-tests for continuous variables 
and with Fisher’s exact tests for categorical variables. Nonparametric Mann-Whitney U tests 
were used in case of skewed distribution.  
Internal consistencies of the domain items of the questionnaires were tested with the 
Cronbach’s Į coefficient, and all domains were within the accepted range of 0.65 to 0.90. 
The level of significance was set at p<0.05 and all tests were two-sided. PASW 
Statistics 18.0 for PC (IBM Corporation, New York, USA) was used for statistical analyses. 
 
Paper I 
In Paper I, a clinically significant change was defined as a change of 10 points on the 0-100 
scale of the UID score, which is commonly recommended 90,91. Linear regression analyses 
were done to examine associations of baseline sociodemographic and cancer related 
independent variables and the degree of PPI (UID score) as the dependent variable. The 
variables that were significant in bivariate analysis were entered into the multivariable model, 
except age65 which was highly correlated to the continuous variable age. Additionally, the 
previously identified risk factors surgical approach, nerve sparing, and comorbidity were also 
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 included, independently of their p-values. Collinearity statistics showed no collinearity 
between age, work status, comorbidity, sexual dysfunction, and incontinence (both the 
variance inflation factors and the tolerance statistics were close to 1 for each of the variables, 
i.e. no multicollinearity). 
Strengths of association were expressed as B and standardized ȕ coefficients. As a 
decreasing value of the dependent variable (UID score 0-100) reflects increasing degree of 
PPI a positive ȕ coefficient represents a positive association and a negative ȕ represents an 
inverse association with increasing degree of PPI. 
 
Paper II 
In Paper II, the two methods of outcome evaluation (satisfaction and using 1 pad/day) were 
compared using Cohen’s kappa coefficient of agreement showing a value of ț 0.25, meaning 
a low degree of overlap (i.e. they were statistically independent). The ț coefficient 
compensates for agreement by chance. 
 
Paper III 
In Paper III, statistically significant group differences were examined for clinical significance 
using effect sizes. For continuous variables, we used Cohen’s coefficient d; and for 2x2 
contingency tables, the differences between arcsine transformed proportions. Effect size 
values 0.40 were considered as clinically significant based on the recommendations of 
Cohen and Sloan et al. 93,94.  
The associations between independent variables and poor QOL as dependent variable 
were analyzed with bivariate and multivariable logistic regression analyses. The strengths of 
association were expressed as odds ratios (ORs), and 95% confidence intervals (CI) were 
given as appropriate. The explanatory power of each model was given as Nagelkerke’s R2. 
 
2.4.5. Ethics 
The Regional Committee for Medicine and Health Research Ethics of South-East Norway 
and the institutional review board at OUH approved the studies of this thesis. All patients 
returning questionnaires gave written, informed consent.
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 2.5. Design considerations and possible errors 
 
The study designs of Papers I and II were prospective follow-up studies, while the study 
design of Paper III was cross-sectional. The cross-sectional design and the lack of a sham-
operated control group in the study of Paper III preclude any conclusions regarding causality 
of the associations with poor QOL in patients operated with an AUS. 
 Measurement error in clinical studies can be divided into random and systematic errors. 
Random errors are due to random fluctuations (or chance) in the data collected. The effects of 
random error are predictable; it causes larger variance, i.e. less precise estimates, which in 
general leads to underestimates of relative risks.  
Systematic errors (or bias) lead to erroneous associations between exposure and 
disease expression. The effects of systematic error are not predictable and can lead to over- or 
under-estimated effects. Examples of systematic errors are selection bias, information bias, 
and confounding 201,202. 
 Selection bias occurs when the criteria for selecting subjects into a study differ between 
‘index’ and ‘comparison’ subjects, i.e. the selected participants are different from non-
participants or cases are different from controls. In all of our samples the patients were 
consecutively enrolled, and that method precluded selection bias. We also made attrition 
analyses in all three papers, documenting that the participants and non-participants did not 
differ significantly on key variables. 
In information bias the nature or quality of measurement differs between ‘index’ and 
‘comparison’ subjects (misclassification of exposure and/or disease). Non-differential 
misclassification (same for both ‘index’ and ‘comparison’ subjects) leads to more serious 
error, i.e. bias, than differential misclassification. Based on questionnaire responses we have 
classified the patients in paper I and II concerning their urinary leakage. The variation in the 
patients’ rating of themselves in this regard represents random error rather than information 
bias. 
Confounding is the distortion or mixing of effects between an exposure, an outcome, 
and a third variable known as a confounder. Confounding leads to a distorted association 
between the exposure and the outcome. We therefore adjusted for available key variables, like 
sociodemographics, PCa stage and surgical approach, when analyzing for significant 
associations to avoid the problem of confounding as much as possible. Some confounders, 
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 like body mass index (BMI) and serum testosterone level 203, were impossible to adjust for in 
our studies, however, and they may represent a source of error not identifiable in our studies.  
These types of bias can be avoided by randomization of patients; otherwise attrition 
analyses of the non-participants’ known variables represent a helpful control. Attrition 
analyses in all three sub-studies in this thesis showed that there were no significant 
differences between participants and non-participants on key variables. The only exception 
was in study II, where the participants had higher mean UID score than non-participants, i.e. 
the participants were more representative for our objective to perform urodynamics in 
patients with severe PPI.  
In order to evaluate generalizability of the prospective studies of AEs after RP (Papers 
I and II), an attrition analysis was originally done for a substudy of the NUCG VII study 184. 
The attrition analysis compared some of the patients included in NUCG VII study (N=521) 
with a control group (N=591) of non-included patients who underwent RP during the study 
period, regarding age, RRP vs. RARP, pT category and RP specimen Gleason score (data 
provided by the Norwegian Prostate Cancer Registry). There was a significantly higher 
proportion of RARP in the study sample compared to the control group, otherwise no other 
significant differences were found. This analysis confirmed the generalizability to the rest of 
Norwegian urological departments. External validity outside of Norwegian health care is 
discussed below. 
 In statistical analysis, there are two additional errors important to be aware of; type I 
and type II statistical errors 204. In an ideal world we would always reject the null hypothesis 
when it is false, and we would not reject the null hypothesis when it is true. Type I error 
involves rejection of a null hypothesis that is actually true, which is equivalent to false 
positives. Alpha (Į) indicates the maximum probability that we have a type I error, for 
example 5% when Į is 0.05 (significance level). This means that there is a 5% probability that 
we will reject a true null hypothesis.  
Type II error occurs when we do not reject a null hypothesis that is false, which is 
equivalent to false negatives. The probability of a type II error is given by the letter beta (ȕ), 
which is related to the power or sensitivity of the study, denoted by 1 – ȕ. In studies with 
small samples there is a higher risk of type II errors than in studies with larger samples. There 
was a considerable risk of type II error in both Papers II and III due to small sample size, i.e. 
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 that we missed significant associations due to low statistical power. Therefore, the results of 
these studies should be verified by studies with larger samples.   
There are a few other terms and concepts that are relevant when dealing with patient-
reported outcome measures (PROM), including validity, reliability, and responsiveness, also 
known as psychometric properties of an instrument. The questionnaires used in this thesis are 
internationally validated and recommended when studying AEs after RP (the UCLA-PCI, the 
EPIC-50, the EPIC-26, and the SF-12) 97,99. 
Validity refers to “the degree to which an instrument measures the construct(s) it 
purports to measure” 205. Validity contains the following concepts: face validity/descriptive 
validity (the instrument obviously seems to measure what it claims), content validity (the 
instrument measures what it claims to measure), construct validity (correlation with other 
instruments measuring the same construct), criterion validity (adequate reflection of a “gold 
standard”), and predictive validity (the instrument is able to predict the outcomes, like AEs). 
The instruments used in papers I-III fulfilled most of these types of validity. 
In the medical literature we also find the terms internal validity (if sound conclusions 
based on the study is warranted) and external validity (generalizability of the findings to other 
samples or situations), referring to study design rather than to the instruments used. Both are 
of course of great importance when discussing results of a study. In the three sub-studies we 
make no assumptions of cause and effect, we only report on associations and predictive 
variables. However, external validity is discussed in Paper I.  
Our results (Paper I) were obtained in a health care system without population-based 
PSA screening, in which more than half of the patients were operated on by high volume 
surgeons (greater than 50 RP’s per year) and more than two-thirds underwent RARP, which is 
similar to the current practice in many other countries in Europe and in North America. 
Therefore, we consider that our results can be generalized beyond Norway and have some 
external validity. The prevalence of PPI and associated risk factors that we found may well be 
relevant to other samples in Europe and in North America. 
Reliability refers to the consistency and reproducibility of an instrument 205. The 
concept reliability contains internal consistency (interrelatedness among the items), reliability 
(variance reflecting true differences), test-retest reliability (variance over time), and 
measurement error (error not caused by true changes). For example, the internal consistency 
of items within a domain can be tested with Cronbach’s Į coefficient. It should be in the 
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 range of 0.65-0.90, as higher values indicate unnecessary overlap 201,206. The internal 
consistency of each domain of the relevant instruments used in this thesis (the EPIC, the 
HADS, and the EPQ) was calculated for our samples and all were found to be satisfactory. 
Responsiveness (sensitivity to change) refers to the ability of an instrument to detect 
change over time in the construct to be measured 205.  
Response shift is not a property of the instrument but rather a phenomenon that may 
occur to individuals over time during a study. It refers to an adaptation of the response 
resulting from changes in an individual’s internal standards, values, or conceptualization of 
AEs/QOL and can affect the reliability and validity of the instrument in use 87,207,208. 
Response shift may arise from a change in the individual’s health over time and leads to a 
change in how that individual views their AEs and QOL, i.e. getting used to a certain 
dysfunction. This may in turn lead to ambiguous or paradoxical findings and can be hard to 
correct for but is important to be aware of when analyzing changes in QOL over time. This 
phenomenon may be relevant for patients with PPI, both when reporting urinary AEs after RP 
as time goes by, and when reporting outcome and QOL after surgical treatment of PPI. Both 
of which can be related to preoperative expectations. Response shift is difficult to estimate, 
and the suggested methods are not generally accepted 208. Therefore we did not do any such 
calculations. However, it is especially important to bear in mind when analyzing the results of 
Papers II and III of this thesis. 
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 2.6. Main findings 
 
Paper I 
The aims of this study were to evaluate the prevalence of patient-reported continence and 
incontinence before and 12 months after RP applying different definitions, as well as 
analyzing the changes, determine the descriptive validity of the PPI stratification proposed by 
Ellison et al., and to study baseline predictors of persistent PPI. 
 
1) Prevalence, incontinence degree and changes (Figure 10, Table 5) 
At baseline 513 patients (70%) reported total urinary control (perfect continence), 212 
patients (29%) had occasional dribbling without pad use and 10 patients (1%) used pads daily. 
Based on the stratification of Ellison et al. 696 patients (95%) had no/mild, 30 (4%) had 
moderate and 9 (1%) had severe incontinence at baseline.  
 
 
 
Figure 10. Prevalence of continence and incontinence before and after RP 
A, continence categories described by Herschorn et al. based on two of the UID items ‘urinary 
control’ and ‘pad use’. B, incontinence stratification based on Ellison et al. 
Green areas indicate improved continence. Red areas indicate worse continence. Blue areas indicate 
stable or little change. Hatched area indicates stable or worse (more pads used). 
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 At 12-month follow-up 195 patients (26%) reported total urinary control, 249 (34%) 
had occasional dribbling without pad use and 291 (40%) used pads daily. According to 
Ellison et al. 428 patients (58%) had no/mild, 120 (16%) had moderate and 187 (25%) had 
severe PPI at 12 months.  
Figure 10 and Table 5 show changes from baseline to 12 months. When the 513 
patients (70%) with total urinary control preoperatively were classified according to 
Herschorn et al. at the 12-month follow-up, 32% still had total urinary control, 32% had 
occasional dribbling and 36% used pads (Figure 10). Of the 222 patients (30%) with 
incontinence preoperatively 14% reported better continence, 41% were stable and 45% had 
worse incontinence at follow-up. The relative risk was 1.29, i.e. the risk of PPI was 29% 
higher in patients who were preoperatively incontinent vs. continent. 
Comparing changes in continence status according to the three continence categories 
or change in continuous UID score revealed moderate agreement (k=0.69). Comparing 
changes according to the continence categories described by Herschorn et al. and the PPI 
stratification by Ellison et al. showed less agreement (k=0.47). According to Ellison et al. a 
larger proportion of patients were defined as stable compared to the two other methods 
(58% vs. 35% to 38%, p <0.001, Table 5). 
 
Table 5. Continence status change from baseline to 12 months after RP 
UID continence 
category change a 
Improved  
N (%) 
Stable  
N (%) 
Worse  
N (%) 
Total  
N (%) 
Continuous score b   
      Improved  14 (44) 18 (56) 0 32 (100) 
      Stable 12 (5) 208 (81) 36 (14) 256 (100) 
      Worse 0 51 (11) 396 (89) 447 (100) 
Stratification c     
      Improved  7 (22) 25 (78) 0 32 (100) 
      Stable 6 (2) 234 (91) 16 (6) 256 (100) 
      Worse 0 169 (38) 278 (62) 447 (100) 
a UID= Urinary Incontience Domain. Based on pad use and urinary control (total control, leakage but no pads or 
pads according to Herschorn et al. b Change of 10 or more points on 0 to 100 scale from baseline to 12 months 
after RP was defined as change (k= 0.69). c According to Ellison et al11 (k= 0.47). 
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 2) Descriptive validity of the stratification of PPI by Ellison et al. (Table 6) 
According to the stratification proposed by Ellison et al., the prevalence of severe PPI was 
25% (95% CI 22%-29%) in our sample 12 months after RP. However, when severe PPI was 
defined as total incontinence, 3% of patients reported ‘no urinary control’ at 12 months, 
including 1% of those younger than 65 years and 6% of men 65 years old or older (p <0.001).  
 
Table 6. Responses to the urinary incontinence domain (UID) before (baseline)  
and 12 months after radical prostatectomy (Paper I) 
Question: How often have you leaked urine the past for weeks? 
Response item Baseline, N (%) 12 months, N (%) 
More than once a day 20 (2.7) 324 (44.1) 
About once a day 21 (2.8) 56 (7.6) 
More than once a week 9 (1.2) 54 (7.3) 
About once a week 35 (4.7) 97 (13.2) 
Rarely or never 650 (88.4) 204 (27.8) 
Question: Which of the following best describes your urinary control? 
Response item Baseline, N (%) 12 months, N (%) 
Total control 514 (69.9) 195 (26.5) 
Occasional dribbling 1 (0.1) 480 (65.3) 
Frequent dribbling 215 (29.3) 39 (5.3) 
No control 5 (0.7) 21 (2.9) 
Question: How many pads did you use per day to control urinary leakage? 
Response item Baseline, N (%) 12 months, N (%) 
None 725 (98.6) 444 (60.4) 
1 pad per day 7 (1.0) 139 (18.9) 
2 pads per day 2 (0.3) 98 (13.3) 
3 or more pads per day 1 (0.1) 54 (7.3) 
Question: How big a problem, if any, has dripping or leaking urine been for you? 
Response item Baseline, N (%) 12 months, N (%) 
No problem 605 (82.3) 315 (42.9) 
Very small problem 100 (13.6) 194 (26.4) 
Small problem 16 (2.2) 94 (12.8) 
Moderate problem 13 (1.8) 84 (11.4) 
Big problem 1 (0.1) 48 (6.5) 
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3) Baseline predictors of PPI at 12 months (Table 7) 
On bivariate analysis the preoperative variables age 65 years or greater, not working, sexual 
dysfunction and incontinence were significantly associated with PPI at 12 months. No 
significant association was observed in D’Amico risk group, surgical methods, nerve sparing 
technique or pathological T stage. On multivariable analysis only preoperative urinary 
incontinence and sexual dysfunction remained significant predictors of persistent PPI 12 
months after RP. 
 
 
Table 7. Linear regression analysis of baseline and cancer related variables associated 
with PPI at 12-month follow-up in 735 patients based on continuous UID score  
 Bivariate analysis Multivariable analysis a 
Variables B ȕ p-value B ȕ p-value 
Baseline 
     Continent b  
     Age 
     Currently working  
     Comorbidity present 
     Sexual dysfunction c 
Clinical T stage: 
    T2a 
    T2b-T2c 
    T3 
Surgical approach: 
    RARP 
    RRP     
Nerve sparing d 
 
-10.0 
0.73 
-8.31 
3.90 
0.23 
 
1.00 
4.17 
8.23 
 
1.00 
3.35 
-3.01 
 
-0.17 
0.14 
-0.15 
0.07 
0.21 
 
 
0.05 
0.07 
 
 
0.06 
-0.05 
 
<0.001 
<0.001 
<0.001 
0.07 
<0.001 
 
 
0.15 
0.08 
 
 
0.14 
0.14 
 
-6.11 
-0.12 
-3.57 
-2.78 
0.21 
 
1.00 
3.52 
9.42 
 
1.00 
3.71 
-1.79 
 
-0.16 
-0.02 
-0.06 
-0.05 
0.19 
 
 
0.05 
0.08 
 
 
0.06 
-0.03 
 
<0.001 
0.70 
0.20 
0.20 
<0.001 
 
 
0.25 
0.05 
 
 
0.11 
0.41 
a All variables significant on bivariate analysis were entered in multivariable analysis except age 65 years, in 
addition to some controversial variables of special interest. Variables not entered in multivariable analysis are 
not shown in this table. b Based on patient reported total urinary control at baseline vs not. c Based on 
continuous sexual domain score 0 to 100 at baseline. d Based on surgeon reported unilateral and bilateral 
technique. 
 
 
 
 Paper II 
The aims of this study were: 1) to describe the results of the clinical examination of patients 
with severe PPI, 2) to collect patient-reported outcome of PPI surgery, and 3) to study the 
associations between 1) and 2). 
 
1) Clinical findings 
The 76 participating patients used 1-13 pads/24 hours and leaked 4-1870g/24 hours. All 
patients but one complained of SUI (thus being categorized as having ISD) and 12 
complained of urgency urinary incontinence (UUI). On free uroflowmetry and post-void 
residual measurement, three patients had reduced bladder voiding efficiency (BVE 46%-68%), 
neither of whom had a stenosis but weak bladder contractility (low bladder contractility index, 
BCI). On invasive urodynamics 52 patients (68%) had bladder dysfunction. Altogether, ISD 
was coexisting with one or more bladder dysfunctions in 51 patients (67%) and ISD was the 
only dysfunction in 24 patients (32%).  
 
2) Outcome of PPI surgery 
Successful outcome of PPI surgery was defined in two ways: Satisfaction and use of 1 
pad/day (‘success’). Thirty-two patients (74%) were satisfied (17 ’very satisfied’, 15 
‘satisfied’) and eleven (26%) were dissatisfied (8 ‘uncertain’, 3 ‘dissatisfied’) with the 
outcome of surgery. Fifteen patients did no longer use pads, 18 used 1 pad/day (thus 33 
(77%) in the ’success’ group), five used 2 pads/day, and five used 3 pads/day. 
 
3) Associations between clinical findings and outcome of PPI surgery 
Preoperative urodynamic bladder dysfunction and amount of leakage (g/24h) were not 
significantly associated with either method of evaluating surgical outcome (satisfaction and 
pad use).  
Using fewer pads preoperatively, a higher preoperative mean UID score, and a longer 
PPI interval (time from RP to PPI surgery) were positively associated with the outcome 
measure success (using 1 pad). A longer PPI interval was the only preoperative variable 
positively associated with satisfaction.  
Finally, patients with presence of urodynamic bladder dysfunction preoperatively 
were compared to those without. No significant differences were observed regarding 
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 preoperative amount of leakage, pad use, or mean UID score, postoperative UID and IRR 
scores, or outcome of PPI surgery. 
 
Paper III 
The aims of this study were study the prevalence of poor generic QOL in patients who had an 
AUS implanted for PPI, comparing with controls, and to identify variables associated with 
poor generic QOL, by comparing with those reporting better QOL. 
 
1) Prevalence of poor QOL 
At a median of 26 months after implantation of an AUS, 30 of the 85 patients, i.e. 35% (95% 
CI 25–45%) of the cases showed poor QOL compared with 27% (95% CI 24–31%) of the 
controls (P = 0.97 adjusted for age and work status).  
 
2) QOL group comparisons  
Comparing the poor and the better QOL groups, no significant differences were observed 
regarding preoperative features like urodynamic abnormalities and pad weight/24h. In 
bivariate analyses, urinary and sexual problems were significantly more common in the poor 
QOL group compared with the better QOL group. The presence of somatic comorbidity, 
reduced work ability, surgical revision of the AUS, anxiety and depression were significantly 
associated with poor generic QOL.  
 
3) Independent variables significantly associated with poor generic QOL 
In multivariable analysis, only reduced work ability and increased level of depression 
remained strongly associated with poor QOL. Our hypothesis of the strong influence of 
urinary incontinence problems on generic QOL was not supported in the study.  
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  2.7. Discussion  
 
Paper I 
Aim 1 
Perfect continence (total urinary control) was reported by 70% at baseline and by 26% 
12 months after RP. However, if we include those with occasional leakage but no pad use, 
which is commonly done 144,146, ‘continence rates’ would be 99% and 60% at baseline and 12 
months, respectively. Thus, the definition applied plays a major role in reported prevalence 
rates. Preoperative continence rates are rarely reported in the literature. The ‘perfect 
continence rate’ 12 months after RP has been reported to be 33% to 87% and the ‘continence 
rate’ (i.e. no pad use) 65% to 98%, somewhat higher than we observed 114,144,146.  
When defined as any pad use or any leakage, previously reported PPI rates are 2% to 
35% and 11% to 72%, respectively (Table 8) 114,146. In contrast, as many as 40% of our 
patients used pads daily and 74% reported any degree of leakage 12 months postoperatively. 
The reason for this high prevalence may have been older age and more advanced PCa in our 
sample, as well as cultural differences with lower thresholds for reporting urinary leakage and 
pad use 209.  
 
Table 8. Definitions of incontinence 12 months after radical prostatectomy 
Definition Reported rates Current study 
Any leakage 11% - 72%  114,144,146 74% 
Any use of pads 2% - 35%  114,144,146 40% 
Frequent leakage/no control 10% a  210 8% 
Total incontinence 5% - 10%  150 3% 
EPIC UID score 0-49 b 6%  211 25% 
Require surgery 5% - 9%  114,115 7% 
Moderate/severe bother 22%  212 18% 
a Reported rate at 24 months after RP.  b EPIC-26 Urinary Incontinence Domain (scale 0-100). 
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 Irritative/obstructive symptoms, i.e. symptoms indicative of bladder dysfunction or 
obstruction (prostate enlargement preoperatively, anastomosis stenosis postoperatively), 
usually improve after RP 112,122;138,213. On the other hand, the prevalence of 
irritative/obstructive symptoms are progressively increasing over time in men in the general 
population, patients with PCa under WW, and patients with PCa treated with RT. This 
difference (RP vs. general population, WW, RT) suggests that the prostate is the primary 
contributor to these symptoms in men and that RP has a therapeutic benefit, at least in 
patients with these symptoms before RP 122,213. However, men with little or no 
irritative/obstructive symptoms before RP may experience an increase in such symptoms 
following RP due to de novo bladder dysfunctions or obstruction 122,213. 
These preoperative symptoms of urgency incontinence, postmicturition dribble and 
overflow incontinence may thus improve with de-obstruction after RP while preoperative 
stress urinary incontinence does not improve 144,214. Many PPI studies only included continent 
patients at baseline and changes in continence status are regularly presumed to be from better 
to worse, i.e. from continence to incontinence 146. However, we included patients who were 
incontinent at baseline and found that 14% of them improved at follow-up, probably due to 
relief of obstruction and improvement of urgency incontinence, postmicturition dribble and 
overflow incontinence. 
 
Aim 2 
Validated symptom scales with several items of more or less objective (pad use) and 
subjective (bother) experience, like the EPIC-26, may be useful when grading PPI, as several 
different aspects of urinary leakage are considered 82,149,187,215,215. However, there is not yet 
international consensus regarding stratification or grading of urinary incontinence into mild, 
moderate and severe forms.  
Some authors have proposed ‘severe incontinence’ to be ‘total incontinence’ while 
Ellison et al. recently proposed a score of 0-49 on the 0-100 scale of the EPIC-26 UID for 
‘severe incontinence’, which includes a lot more patients than those reporting ‘total 
incontinence’150,187. In our opinion, the cut-off that Ellison et al. used for severe PPI seems 
unreasonably lenient since it leads to inclusion of a considerable proportion of patients with 
moderate PPI in the severe PPI group. For example, a patient reporting the combination of 
occasional dribbling (score 67), leaking once daily (score 25), using one pad (score 67) and 
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 considering it a moderate problem (score 25) would have a mean UID score of 46, and thus 
being a case with severe PPI according to Ellison et al.  
In our sample at follow-up the prevalence of severe PPI according to Ellison et al. was 
25% (95% CI 22%-29%), which is quite high, particularly compared to the 6% that Ellison et 
al. reported in their sample 211. However, when severe PPI was defined as ‘total incontinence’, 
previously reported rates were 5% to 10%, increasing with age 150. These values are in better 
agreement with our finding that 3% of patients reported no urinary control at 12 months, 
including 1% of those younger than 65 years and 6% of patients 65 years or older (p <0.001).  
Therefore, our findings do not support the descriptive validity of the severe PPI 
definition of Ellison et al. and our hypothesis was not supported. 
On the other end of the scale (no/mild incontinence), Krupski et al. found that of 
patients reporting a score of 80-100 on the 0-100 scale of  the UCLA-PCI, 99% used no pads, 
71% reported total control, and 65% reported not leaking urine at all 4, indicating that these 
different aspects of urinary incontinence do not always correlate perfectly.  
Nonetheless, subjective bother (problem with urinary leakage) should probably be 
included in a PPI severity grading since this aspect of urinary leakage decreases QOL and 
drives treatment 212. However, the cut-offs for such a grading remain to be identified.  
Should bother or pad use be weighted more when defining PPI severity? It is 
important to distinguish between patients who leak enough to require pads and those who do 
not since pad use significantly affects QOL 4,212,216. However, in our study patients with all 
degrees of PPI, including those not using pads, reported a ‘moderate/big problem with 
leakage’. For an international consensus the PPI severity grading should be meaningful and 
useful, and not only easy to apply, such as ‘pad use’. The scores on the 0-100 scale of the 
EPIC-26 UID do probably not mean much to the individual patient though, and may therefore 
seem quite meaningless during preoperative counselling. These scores may rather be useful 
when reporting AEs and QOL outcomes after RP. 
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 Aim 3 
Older age and preoperative urinary incontinence can be considered established predictors of 
PPI, as identified by previous studies 144,217. Nevertheless, several of our patients with 
preoperative incontinence reported improvement, probably related to relief of obstruction. 
Older age was no longer significant when adjusting for preoperative sexual dysfunction and 
urinary incontinence, which emerged as more important. 
Preoperative sexual dysfunction was the strongest predictor of PPI in this study. 
Preoperative erectile dysfunction is a predictor of PPI with the hypothesis that erectile 
dysfunction might be a marker of pelvic vascular disease that eventually affects the function 
of the external urinary sphincter 218,218,219.  
Surprisingly, unemployment (not working) preoperatively was associated with PPI, 
also when adjusted for age. To our knowledge this is a new finding. Employment may 
represent health and stamina beyond age and comorbidity, and may thereby explain the 
negative association with PPI. Unemployment was a stronger predictor than older age. 
However, neither was significant in the multivariable analysis where only preoperative 
incontinence and sexual dysfunction remained significant.  
There are conflicting findings in the literature on the effect of PCa stage, surgical 
approach and nerve sparing on PPI, but most large series show no significant associations, 
corresponding to our findings 115,217.  
We could not adjust for some previously identified risk factors of PPI, including 
metabolic factors such as waist circumference, body mass index, testosterone level and 
annual surgeon RP volume. A previous study of a subsample of our patients showed no 
significant association between surgeon volume and PPI, but RP at university hospitals was 
more favourable than at community hospitals 184.  
 
Strengths and limitations 
We used well-established questionnaires and had a large sample size and high response rates 
to the questionnaires. Participants did not differ from non-participants so that they may be 
considered representative of the 844 patients primarily included in the study. 
Our results were obtained in a health care system without population-based PSA 
screening, in which more than half of the patients were operated on by high volume surgeons 
(greater than 50 RP/year) and more than two-thirds underwent RARP. This practice is similar 
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 to that of many other countries in Europe and in North America. Therefore, we consider that 
our results in this study can be generalized beyond Norway. 
The missing discrimination of the type of urinary incontinence is a limitation. The 12-
month follow-up could be considered too short for a study of persistent PPI, although little 
improvement is expected after that time. The major limitation in reporting PPI prevalence is 
the lack of international consensus on the optimal way to define, assess and grade PPI. 
 
Paper II 
Aim 1 
Concerning urodynamic findings after RP, the Committee on Surgical Treatment of Urinary 
Incontinence in Men (2010 and 2013) stated that ISD was the sole finding in more than 
two-thirds of patients with PPI, and that a combination of sphincter and bladder dysfunction 
was less common 115,144,144. Porena et al. (2007) found in their review that previous reports 
varied widely concerning bladder dysfunction following RP 137. The studies referred to in 
these reviews had very different follow-up and timing of urodynamic evaluation following 
RP, though, which may have contributed to the different findings. 
Kadono et al. recently published their results comparing urodynamics in 87 patients 
before and 9-11 days after RARP 220. Bladder dysfunctions were present both preoperatively 
and postoperatively, with significant changes in some parameters (bladder capacity, bladder 
compliance), while the proportion of patients with DO did not increase significantly (25% to 
29%, p=0.44). ISD was found in none preoperatively and in 86% postoperatively.  
We found urodynamic abnormalities coexisting with ISD in two-thirds of our patients 
with persistent severe PPI more than one year after RP. Among the 76 patients with self-
reported persistent severe PPI 99% had intrinsic sphincter deficiency (ISD), in 67% 
coexisting with urodynamic bladder dysfunction, DO in 29%. Although not directly 
comparable, due to different length of follow-up and patient sampling method, our results are 
quite similar to the abovementioned after RP.  
However, some findings on invasive urodynamics were contradictory to findings on 
free uroflowmetry with post-void residual urine measurement and urethrocystoscopy in our 
patients. The bladder contractility and the bladder outlet can usually be assessed by a 
pressure-flow study, but standard urodynamic definitions may be invalid in prostatectomized 
men 161,221, which could explain these contradictons: According to Schäfer’s nomogram and 
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 the bladder contractility index (BCI) 38 of our patients were defined as having weak bladder 
contractility (low BCI). However, low BCI was confirmed as clinically relevant only in the 
three patients with reduced bladder voiding efficiency (BVE <80%), i.e. those with 
significant post-void residual urine, and this finding is in accordance with previous 
studies 137,222,222. Similarly, 23 patients were regarded as ‘obstructed’ or ‘equivocal’ according 
to the bladder outlet obstruction index (BOOI); but 19 had normal free flow and/or no 
stenosis. Valsalva voiding was not significantly more common in patients with high BOOI or 
low BCI.  
Elliott and Comiter (2012) questioned the use of the BCI in prostatectomized men 
since it was not originally intended for use in that context, but rather in patients with prostatic 
obstruction 223. After RP the urethra offers little resistance to micturition, thus low detrusor 
pressures are sufficient for a normal urinary flow rate 161. Hence, the false positive rate of 
weak contractility (i.e. BCI <100) may be high in prostatectomized patients as the 
Pdet@Qmax can be very low in these patients.  
 Instead, Elliott and Comiter suggested the use of maximum isometric pressure (Piso) 
during mid-void while occluding the penile urethra (mechanical stop test). When using a 
Piso <50cmH2O as a cut-off for detrusor underactivity the proportion of men with PPI 
diagnosed with weak contractility was reduced to 40% compared with 68% when using the 
BCI. Of those with detrusor underactivity using the BCI criteria, 57% had a Piso value 
suggesting normal strength 223. The Piso method could give more correct results in 
prostatectomized men, but larger studies are needed to verify that. 
Other proposed definitions of detrusor underactivity after RP are Qmax <12 ml/sec 
and Pdet@Qmax <30 cmH2O 161, Qmax <15 ml/sec and Pdet@Qmax <25 cmH2O 224, and 
Qmax <15 ml/sec and Pdet@Qmax <20 cmH2O 225. A recent review regarding detrusor 
underactivity (of any etiology), confirms the confusion around the methods of evaluating 
detrusor contractility and states that there is a need to reach a consensus 221. 
Hence, the indices BOOI and BCI can be misleading in patients with PPI, and should 
be interpreted with care and rather be used in addition to free uroflowmetry with post-void 
residual measurement and urethrocystoscopy. 
Thus, when excluding those with only high BOOI and/or low BCI in our sample, the 
proportion of patients with bladder dysfunctions coexisting with ISD was reduced from 67% 
to 38%. Nevertheless, bladder dysfunction, with or without this exclusion, was not 
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 significantly associated with the amount of urinary leakage (g/24h) or mean UID score prior 
to PPI surgery, being referred to surgery, or the outcome of surgery. It should be emphasized 
however, that all the patients with symptomatic DO (i.e. UUI) preoperatively had an AUS 
implanted, not a sling. 
 
Aim 2 
Of the 43 operated patients, satisfaction was reported by 74% and using 1 pad/day by 77%. 
These results are comparable to previously published reports of outcome after surgery with an 
AUS or a sling for PPI 144. 
 
Aim 3 
Urodynamic investigation is recommended in the evaluation of PPI, especially prior to 
surgical treatment, by the Fourth International Consultation on Incontinence, the European 
Association of Urology guidelines, and the American Urological Association 
guidelines 67,115,162-164. The recommendation of urodynamic investigation before surgical 
treatment of PPI is not evidence-based, however 165,166.  
Most patients tolerate invasive urodynamics well, but in a recent study by Suskind et al., 
38% of the patients reported physical or emotional discomfort, with placement of the urethral 
catheter causing the most physical discomfort (Suskind et al. 2014a). There is also a risk of 
AEs after urodynamics, especially urinary tract infections, although rare 226. Hence, 
unnecessary invasive diagnostic procedures should be avoided. Urodynamics should only be 
performed when there is a question that can be answered and that answer would affect 
treatment choice or outcome 227. 
The 2014 EAU Guidelines on Urinary Incontinence state that no studies have 
examined the clinical usefulness of urodynamics in patients with PPI, and that the ability of 
urodynamics to predict surgical outcome for PPI is inconsistent 172. It has been shown that 
preoperative urodynamic abnormalities have no adverse effect on the outcome of PPI surgery, 
which is in agreement with the findings in our study 168,169,228-230. The presence of bladder 
dysfunction preoperatively was not predictive of the outcome of PPI surgery in our study; 
hence our hypothesis was not supported.  
In a recent review by Jura and Comiter (2014), the role of urodynamics in patients 
with PPI is comprehensively discussed 227. The available evidence indicates that the non-
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 compressive sling (AdVance®) and the AUS (AMS800®) are not contraindicated in case of 
detrusor underactivity or overactivity, while the compressive slings (InVance®, TOMS®, 
Argus®) should probably be avoided in such cases. They suggest that urodynamics are 
unnecessary if the AUS is the treatment of choice, based on amount of leakage, prior RT, 
patient preference, or previous sling/AUS implantation. They pointed out that DO or impaired 
compliance (in nonradiated patients) typically resolves after PPI surgery as the normal cycle 
of adequate filling and emptying is re-established 227. Their review and conclusions are in 
accordance with our findings.  
A longer PPI interval was the only preoperative variable associated with both methods 
of evaluating successful outcome in our study. This observation has not been reported 
previously and is difficult to explain. It could be related to a response shift in the patients, i.e. 
getting used to PPI with time and having lower expectations for PPI surgery 207.  
These results rather indicate that invasive urodynamic examinations may be somewhat 
restricted, and not performed in all patients before PPI surgery. Major lower urinary tract 
dysfunctions are important to detect, but will be symptomatic and/or obvious on free 
uroflowmetry with post-void residual measurement, and will subsequently warrant closer 
evaluation with invasive urodynamics/urethrocystoscopy. It is not necessary to identify 
asymptomatic DO preoperatively, however. Latent DO may resolve postoperatively. 
Otherwise, if latent DO becomes symptomatic postoperatively it can be treated medically. 
Finally, a pressure-flow study and contemporary definitions may actually be misleading in 
men with PPI and redundant if the free uroflowmetry is normal, indicating normal bladder 
contractility and outlet. Only if the pathophysiology of PPI is unclear or some form of bladder 
dysfunction is suspected, urodynamics can add important information in the evaluation of PPI. 
 
Strengths and limitations 
We used well-established questionnaires and had high response rates. The attrition analysis 
showed that the attending patients were representative for our objective to perform 
urodynamics in patients with severe PPI. Unfortunately, due to some logistical challenges, not 
all patients underwent complete clinical examination. The small sample undergoing PPI 
surgery poses a considerable risk of type II statistical errors. Additional significant 
associations might have escaped us because of the low statistical power.  
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Paper III 
Aim 1 
At a median of 26 months after implantation of an AUS, 35% of the patients reported poor 
generic QOL, similarly to that observed in controls from the general male population. The 
similarity of the proportions of men with poor versus better generic QOL among cases and 
controls is encouraging. Admittedly, we do not know how much the implantations have 
improved generic QOL in the patients. However, because of limited resources, the 
implantations were restricted to the most bothered patients with incapacitating PPI. We 
therefore believe that the overwhelming majority of patients had highly reduced generic QOL 
before surgery. For most of them, the AUS has reduced their PPI problems considerably, thus 
we believe that it must have affected their normal generic QOL at group level.  
 
Aim 2 
In bivariate analyses, urinary and sexual problems were significantly more common in the 
poor QOL group compared with the better QOL group. The presence of somatic comorbidity, 
reduced work ability, surgical revision, anxiety and depression were significantly associated 
with poor generic QOL. Several of these variables are amenable to diagnostic evaluation and 
eventual counselling or therapy, which should be considered with the aim of improving QOL. 
 
Aim 3 
In multivariable analysis, only reduced work ability and increased level of depression 
remained statistically associated with poor QOL. Our hypothesis of a significant influence of 
urinary incontinence problems on generic QOL was not supported in the present study. 
Do the results of the present study contradict previous reports 175,177,178 of good post-
implantation incontinence-related QOL? By no means, but the present study showed clearly 
that generic QOL, which was our end-point, differs from incontinence-related QOL. Also, in 
the present study, urinary incontinence was an important factor of generic QOL in bivariate 
analyses, but was less important when other factors of daily living, such as work ability and 
mental health, also were taken into account. Furthermore, the present results represent groups 
of patients, and clinicians have to be aware that urinary incontinence still can be a problem 
for the individual patient even after AUS implantation.   
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 The present study is the first to report a discrepancy between incontinence-related and 
generic QOL concerning urinary problems after implantation of AUS for PPI. Although 
evaluation of incontinence-related QOL is important in uro-oncological practice, the results 
show that supplement with generic QOL can be of clinical value when the aim is to improve 
the general well-being of men after RP.  
Urologists, oncologists and general practitioners responsible for follow-up of these 
patients should perhaps take a broader view than only checking for urinary or sexual 
problems. It is well known that depression can reduce work ability, whereas reduced work 
ability can also trigger depression, so the primary cause cannot be disentangled in the present 
cross-sectional study. However, depression is easily tested by self-report or interview, and is 
amenable to both pharmacological and psychotherapeutic interventions in general practice.  
 
Strength and limitations 
We used well-established instruments, and had a high response rate. We also had meaningful 
control data from the general population concerning generic QOL, and the attrition analysis 
showed that we could generalize to our total sample. A limitation was the small sample size, 
with a considerable risk of type II statistical errors. There might be additional significant 
associations between the independent variables and poor QOL that escaped us because of low 
statistical power. In contrast, the associations we observed were both statistically and 
clinically significant despite the low numbers. However, small group sizes resulted in broad 
95% confidence intervals in the regression analyses.  
The major limitation was a lack of pre-surgery generic QOL ratings, even though we 
intensively reviewed the medical records. However, it is with little doubt that the men 
selected for PPI surgery during the study period had incapacitating incontinence, which 
regularly leads to poor generic QOL. 
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 2.8. Conclusions 
 
Paper I – How should continence and incontinence after radical prostatectomy be 
evaluated? A prospective study of patient ratings and changes with time 
The prevalence of patient reported PPI 12 months after RP was high in this prospective study 
regardless of the definition applied: 40% of our patients used pads daily and 74% reported 
any degree of leakage. Severe PPI was reported by 3% to 25%, depending on definition (total 
incontinence or grading by Ellison et al.). In our opinion incontinence may be reported as any 
leakage, and not only as pad use, and grading done on a symptom scale. However, our 
findings cast doubt on the descriptive validity of the PPI stratification introduced by Ellison et 
al. Particularly their severe PPI stratum seems too broad. Further effort should be made to 
reach an international consensus on a PPI severity grading. The strongest predictors of 
persistent PPI were preoperative sexual dysfunction and urinary incontinence but some 
patients with preoperative incontinence improved after RP. PCa-related and treatment related 
variables were not associated with PPI in our study. 
 
Paper II - Severe postprostatectomy incontinence: Is there an association between 
preoperative urodynamic findings and outcome of incontinence surgery? 
Urodynamic bladder dysfunction coexisted with intrinsic sphincter deficiency in 67% of the 
patients with persistent severe PPI, but was not predictive of the outcome of PPI surgery. Our 
results indicate that invasive urodynamic investigation may not be mandatory before PPI 
surgery in patients with pure sphincter deficiency and otherwise normal bladder function and 
outlet assessed by anamnesis, voiding diaries, free uroflowmetry, and post-void residual urine 
measurement. Urodynamics may thus be omitted in up to two thirds of patients in whom 
surgery for PPI is considered without compromising the outcome.  
However, omitting invasive urodynamic examinations requires careful preoperative 
counselling of patients regarding the limited risk of detecting a postoperative diagnosis of 
bladder dysfunction in need of medical therapy. These results should be verified by larger 
studies. 
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 Paper III - Study of generic quality of life in patients operated on for postprostatectomy 
incontinence 
A total of 35% (95% CI 25–45%) of the cases showed poor QOL compared with 27% (95% 
CI 24–31%) of the controls in the general population sample. In bivariate analyses we found 
that urinary and sexual problems were associated with poor generic QOL after surgery for 
PPI. However, in multivariable analyses these problems did not show significant associations 
with poor QOL. In contrast, an increased level of depression and reduced current work ability 
did show significant associations with poor QOL. In case the urologist suspects depression 
during follow-up of the patient, he should be recommended to contact his regular GP for 
further evaluation. 
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 2.9. Clinical implications and future research 
 
Paper I – Prevalence of and risk factors for PPI 
When studying postprostatectomy incontinence (PPI), with the aim of sober patient 
counselling, it is important to be clear, concise and not compare apples and pears (i.e. pads 
and leakage). For both patients and physicians it is important to be aware of widely varying 
prevalence rates, only depending on definition applied, when comparing published reports. 
Rather than making a clear recommendation on how to report and grade PPI, our aim 
has been to show with concrete numbers the differences in PPI prevalence rates according to 
the definitions applied. We have primarily tried to document a problem rather than to solve it. 
In our opinion, major international bodies like the International Continence Society should 
make more definite recommendations on how to report and grade PPI in the near future. 
Meanwhile, there should be full candour when reporting PPI, with disclosure of all patients 
with any leakage, any pad use, and any bother. 
Patients with urinary incontinence and/or sexual dysfunction before RP should be 
informed about the increased risk of experiencing persistent PPI after RP. Assessment of 
these risk factors should be part of routine preoperative counselling, similar to counselling 
given to the PCa patient about treatment modality and expected outcome. When studying risk 
factors for adverse effects after RP in the future, BMI and baseline testosterone level should 
also be assessed. 
 
Papers II and III – Urodynamics and outcome of PPI surgery  
Urodynamic bladder dysfunction was not predictive of the outcome of PPI surgery; hence 
invasive urodynamics may be omitted in up to two thirds of patients in whom surgery for PPI 
is considered without compromising the outcome. However, these results should be verified 
by studies with larger samples or in randomized controlled trials. 
 PPI surgery has an acceptable rate of successful outcome, both when regarding 
satisfaction and pad use. Patients should however be counselled preoperatively that success is 
defined as use of one pad/day or less and that quite a substantial proportion of patients need 
pads after PPI surgery. They can also be informed of our study showing generic QOL similar 
to the general male population. As poor QOL was associated with depression and reduced 
work ability, these aspects should be considered during follow-up. 
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Errata 
 
In the Summary 
2.6. Main findings, Paper I, Table 7: 
There should not be negative signs before the numbers in the rows after the variables T2b-2c, 
T3 and RRP. 
 
Reference list: 
References 39 and 41 are the same, and references 1 and 15 are the same. 
 
In Paper III, Table 1:  
The correct numbers, n (%), for the three cancer related variables should be: 
Table 1. Characteristics of the total sample and the QoL groups  
Variables  Total sample 
(n = 85) 
Better QoL 
(n = 55) 
Poor QoL 
(n = 30) 
p-value 
  Had pelvic radiotherapy 
  Current hormone therapy 
  Relapse of prostate cancer 
15 (18) 
10 (12) 
12 (15) 
10 (19) 
5 (9) 
7 (13) 
5 (17) 
5 (19) 
5 (17) 
0.83 
0.29 
0.75 
 
 

  
 
Appendix: Questionnaires 

  
SPØRSMÅL OM BAKGRUNN OG SYKDOMMER 
Gift  eller samboer…………………………  
Skilt eller separert…………………………..    
Enkemann eller partner har gått bort……….    
Er i forhold, men bor hver for seg…………      
Aldri gift eller samboer…………………….  
Grunnskole, folkeskole eller mindre..……….. 
Ungdomsskole, realskole eller tilsvarende…..   
Gjennomført videregående eller yrkesskole…   
Noe på høgskolenivå…………………………   
Gjennomført høgskole………………………..   
Gjennomført universitetsutdannelse….………   
3. Nedenfor finner du en liste med kroniske lidelser og sykdommer.  
Vennligst sett ett kryss for hver av dem du har eller har hatt i løpet av de siste 12 månedene. 
Har du denne 
Sykdommen? 
Blir du behandlet for 
denne sykdommen? 
Hindrer sykdommen 
deg i aktiviteter? 
 Ja Ja Ja 
a. Hjerneslag…………………………..
b. Høyt blodtrykk……………………..    
c. Astma, kronisk bronkitt eller KOLS.    
d. Sukkersyke…………………………    
e. Nyresykdom………………………..    
f. Leversykdom……………………….    
g. Anemi eller annen blodsykdom……    
h. Sykdom i skjoldbruskkjertelen…….    
i. Depresjon…………………………..    
j. Slitasjegikt (artrose)………………..    
k. Ryggsmerter………………………..    
l. Leddbetennelse (revma)……………    
……………... 1                          (sett ring rundt ett tall) 
Ja, fulltid……………………….   
Ja, deltid………………………..              
Nei, men søker jobber………….   
Nei, pensjonert………..………..   
Nei, sykmeldt eller på attføring..   
Nei, uføretrygdet………………   
SPØRSMÅL OM PROSTATAKREFTEN DIN 
          
5. Har du fått strålebehandling for prostatakreften din?   Nei            Ja  
6. Har du brukt hormonbehandling for prostatakreften din? Nei  Ja, tidligere   Ja, nå for tiden  
7. Har du hatt tilbakefall av prostatakreften din? 
Nei        Ja     Hvis Ja, for hvor mange år siden? (skriv tallet) ______ 
1. Hvilken sivilstand har du i dag?  
2. Hvor mye utdanning har du gjennomført?  
4. Er du for tiden i inntektsgivende arbeid?  
  
SPØRSMÅL OM URINFUNKSJONEN (Utdrag fra UCLA-PCI) 
Dette avsnittet omhandler din urinfunksjon. Det er kun situasjonen de siste 4 ukene du skal ta i betraktning. 
13. Hvor ofte har du hatt urinlekkasje i løpet av DE SISTE 4 UKENE? 
                                                                       
Hver dag…..............................…  
Omtrent en gang i uken………..  
Sjeldnere enn en gang i uken......   
Aldri.…………….......................
 
Total manglende kontroll (betydelig urinlekkasje) …   
Hyppig urinlekkasje……..…………………..………   
Dråpelekkasje av og til………..………….……..…...   
Ingen lekkasje (full kontroll).……………………..…   
Tre eller flere per dag….…………………………..  
En - to per dag………………..…………….. ………….  
Ingen………………………………………………..  
4. Hvor stort problem har hver av de følgende vært for deg i løpet av DE SISTE 4 
UKENE? 
 
Sett ett kryss pr linje 
Ikke noe 
problem 
Veldig lite 
problem 
Lite 
problem 
Moderat 
problem 
Stort 
problem 
a. Urinlekkasje med våte benklær……      
b. Urinlekkasje som forstyrrer seksuell  
aktivitet……………………      
Ikke noe problem………………………..……...   
Svært lite problem….………………………..…   
Lite problem…………………..……………..…   
Moderat problem…………………………....….   
Stort problem…………………………………...   
1. vor ofte har du hatt urinlekkasje i løpet av DE SIST  4 UKENE? 
2. Hvordan vil du beskrive din kontroll over blæretømmingen i løpet av DE  SISTE 4 
UKENE?  
3. Hvor mange truseinnlegg, bind eller bleier har du vanligvis brukt per dag for 
lekkasje i løpet av DE SISTE 4 UKENE?  
5. Hvor stort problem har du totalt sett hatt med urinfunksjonen DE SISTE 4 
UKENE? 
  
SPØRSMÅL OM URINFUNKSJONEN (EPIC-26 Urinary domain) 
14. Hvor ofte har du hatt urinlekkasje i løpet av DE SISTE 4 UKENE? 
 
Mer enn en gang om dagen……  
Omtrent en gang om dagen……  
Mer enn en gang i uken…….….   
Omtrent en gang i uken………..  
Sjelden eller aldri.……………..
 
Total manglende kontroll (betydelig urinlekkasje) …   
Hyppig urinlekkasje……..…………………..………   
Dråpelekkasje av og til………..………….……..…...   
Ingen lekkasje (full kontroll).……………………..…   
Ingen………………………………………………..  
En per dag………………..…………….. ………….  
To per dag….……………………....................  
Tre eller flere per dag….…………………………..  
4. Hvor stort problem har hver av de følgende vært for deg i løpet av DE SISTE 4 
UKENE? 
Sett ett kryss pr linje 
Ikke noe
problem 
Veldig lite
problem 
Lite
problem 
Moderat
problem 
Stort
problem 
a. Drypping eller urinlekkasje………      
b. Smerte eller brennende følelse  
ved vannlating……………………      
c. Blod i urinen……………………...      
d. Svak urinstråle eller vansker  
med å tømme blæra?......................      
e. Må du late vannet ofte i løpet  
av dagen?......................................      
Ikke noe problem………………………..……...   
Svært lite problem….………………………..…   
Lite problem…………………..……………..…   
Moderat problem…………………………....….   
Stort problem…………………………………...   
 
1. vor ofte har du hatt urinlekkasje i løpet av DE SISTE 4 UKENE?  
2. Hvordan vil du beskrive din kontroll over vannlatingen i løpet av DE  SISTE 4 
UKENE?  
3. Hvor mange truseinnlegg, bind eller bleier har du vanligvis brukt per dag for 
lekkasje i løpet av DE SISTE 4 UKENE?  
5. Samlet sett hvor stort problem har du hatt med urinfunksjonen DE SISTE 4 
UKENE? 
  
 SPØRSMÅL OM SEKSUALFUNKSJONEN (Utdrag fra UCLA-PCI) 
Det neste avsnittet om seksualfunksjon inneholder mange spørsmål av personlig karakter. Vi minner om at 
svarene på dette spørreskjemaet vil bli behandlet konfidensielt og vil bare bli brukt til forskningsformål: Vær 
snill å svare så ærlig som du kan om de siste 4 ukene. 
1. Hvordan vil du gradere det følgende i løpet av de siste 4 ukene? 
Sett ett kryss på hver linje Svært 
dårlig 
Dårlig Rimelig God Svært 
god 
a. Grad av seksuell interesse (lyst)…..      
b. Din evne til å få ereksjon (reisning)…..      
c. Din evne til å få orgasme (klimaks)…..
Ingen ereksjon (reisning)…………………  
Ikke stiv nok til noen seksuell aktivitet…..  
Bare stiv nok til onanering og forspill……  
Tilstrekkelig stivhet for samleie………….    
Aldri ereksjon når jeg har ønsket det………  
Mindre enn halvparten av tiden ……………  
Omtrent halvparten av tiden ……………….   
Mer enn halvparten av tiden ……………….  
Alltid ereksjon når det har vært ønskelig ….   
Aldri……………………..……......................  
Sjelden (mindre enn 25% av tiden).................  
Ikke ofte (mindre enn halvparten av tiden)….  
Ofte (mer enn halvparten av tiden)….............  
Veldig ofte (mer enn 75% av tiden).……...…  
Nei..............……………………..…….........   
Ja, en gang.…………………………..….….  
Ja, mer enn en gang.…..……………..….….  
Svært dårlig……………………..…….........   
Dårlig………………………………..… ….  
Rimelig………………..……………..… ….  
God………….……………………....…. ….  
Svært god……..………………………... …  
2. Hvordan er vanligvis GRADEN av stivhet ved ereksjon?  
3. Hvor OFTE har du oppnådd ereksjon når det har vært ønskelig?  
6. Hvordan vil du karakterisere din evne til å fungere seksuelt de siste 4 ukene?  
4. Hvor ofte har du våknet om morgenen eller natten med ereksjon?  
5. Har du gjennomført samleie i løpet av de siste 4 ukene?  
  
Alltid ……………….......……..…….....  
Oftest ………………………………..…   
Sjelden ………………..……………..…   
Aldri ………….……………………......  
Alltid ……………………..…….........   
Oftest ………………………………..  
Sjelden ………………..……………..
Aldri ………….……………………...  
a) Uten tabletter eller sprøyter 
Ikke aktuelt ……………………..…….......................  
Ikke ereksjon, samleie ikke mulig……………...........  
Samleie mulig i mindre enn halvparten av forsøkene..  
Samleie mulig ved de fleste forsøk ……………....….   
Samleie alltid mulig ……………………………....….   
b) Med tabletter for potens (ikke sprøyter) 
Ikke aktuelt ……………………..…….......................  
Ikke ereksjon, samleie ikke mulig……………...........
Samleie mulig i mindre enn halvparten av forsøkene..  
Samleie mulig ved de fleste forsøk ……………....….   
Samleie alltid mulig ……………………………....….   
c) Etter bruk av sprøyter i penis 
Ikke aktuelt ……………………..…….......................  
Ikke ereksjon, samleie ikke mulig……………...........  
Samleie mulig i mindre enn halvparten av forsøkene..  
Samleie mulig ved de fleste forsøk ……………....….   
Samleie alltid mulig ……………………………....….   
Ikke noe problem……………….………….…   
Svært lite problem..…………………………..   
Lite problem………………………………….   
Moderat problem…..…………………………   
Stort problem…………………………………   
Alltid……………….………….…   
Oftest (mer enn halvparten av gangene)………..   
Ganske ofte (omtrent halvparten av gangene)……. 
Sjelden (mindre enn halvparten av gangene)……   
Aldri…………………………………   
20. Hvor stort problem har din seksualfunksjon vært for deg de siste 4 ukene?  
7. Har du brukt tabletter utskrevet av lege for å bedre seksuell funksjon (potens)?  
8. Har du satt sprøyte/injeksjon i penis for å få bedre ereksjon?  
9. Hvordan vil du beskrive din evne til å gjennomføre samleie uten, eller eventuelt 
med tabletter eller sprøyter i løpet av de siste 4 ukene?  
20. Har du hatt smerter eller ubehag i forbindelse med orgasme/ utløsning? 
  
SPØRSMÅL OM SEKSUALFUNKSJONEN (EPIC-26 Sexual domain) 
Denne delen handler om din nåværende seksualfunksjon og din seksuelle tilfredsstillelse. Mange av spørsmålene er 
svært personlige, men vi minner om at svarene dine blir behandlet konfidensielt og bare blir brukt til forskning.  
 
Tabletter                              Ja                 Nei  
Injeksjoner/ Sprøyter          Ja                 Nei  
Vakumpumpe                     Ja Nei
Bondil urethralstift Ja  Nei  
16. Hvordan vil du gradere det følgende i løpet av DE SISTE 4 UKENE? 
Sett ett kryss på hver linje Svært 
dårlig 
Dårlig Rimelig God Svært 
god 
a. Din evne til å få ereksjon (reisning)…..      
b. Din evne til å få orgasme (klimaks)…..      
Ingen ereksjon (reisning)…………………  
Ikke stiv nok til noen seksuell aktivitet…..  
Bare stiv nok til onanering og forspill……
Tilstrekkelig stivhet for samleie………….    
Aldri ereksjon når jeg har ønsket det………  
Mindre enn halvparten av tiden ……………  
Omtrent halvparten av tiden ……………….   
Mer enn halvparten av tiden ……………….  
Alltid ereksjon når jeg har ønsket det ……...   
Svært dårlig……………………..…….........   
Dårlig………………………………..… ….  
Rimelig………………..……………..… ….  
God………….……………………....…. ….  
Svært god……..………………………... …  
Ikke noe problem……………….………….…   
Svært lite problem..…………………………..   
Lite problem………………………………….   
Moderat problem…..…………………………   
Stort problem…………………………………   
15. Dersom du bruker hjelpemidler for ereksjonen, merk av hvilke du har brukt i 
løpet av DE SISTE 4 UKENE?  
17. Hvordan har KVALITETEN på ereksjonen vært i løpet av DE SISTE 4 UKENE?  
18. Hvor OFTE har du oppnådd ereksjon når det har vært ønskelig?  
19. Samlet sett hvordan vil du karakterisere din evne til å fungere seksuelt DE SISTE 
4 UKENE?  
20. Samlet sett hvor stort problem har din seksualfunksjon eller mangel på 
seksualfunksjon vært for deg DE SISTE 4 UKENE?  
  
SPØRSMÅL OM TARMFUNKSJONEN (EPIC-26 Bowel domain) 
 
 
a. Sterk, umiddelbar avføringstrang…..           
b. Hyppigere avføring…………………           
c. Mistet kontroll over avføringen…….
d. Blod i avføringen……………………           
e. Smerter i magen, bekkenet eller  
i endetarmen………………………..           
Ikke noe problem………………………      
Svært lite problem….………………….  
Lite problem…………………..……….
Moderat problem………………………   
Stort problem…………………………..   
SPØRSMÅL OM ANDRE FUNKSJONER (EPIC-26 Hormonal domain) 
 
26. Hvor stort problem, om noe, har hvert av de følgende vært for deg DE SISTE 4 
UKENE? 
 
Sett ett kryss på hver linje Ikke noe 
problem 
Veldig lite 
problem 
Lite 
problem 
Moderat 
problem 
Stort 
problem 
a. Hetetokter…………………..                   
b. Ømme/svulne bryster………                   
c. Følt deg nedstemt…………..                   
d. Manglet energi……………..                   
e. Vektforandring……………..                   
 
13. Hvor stort problem, om noe, har hver av de følgende vært for deg i løpet av DE 
SISTE 4 UKENE? 
 
Sett ett kryss på hver linje Ikke noe 
problem 
Veldig lite 
problem 
Lite 
problem 
Moderat 
problem 
Stort 
problem 
14. Samlet sett, hvor stort problem har avføringsfunksjonen vært for deg i løpet av 
DE SISTE 4 UKENE?  
  
SPØRSMÅL OM HELSEN (SF-12) 
De første spørsmålene er om helsen din generelt, BÅDE RELATERT og IKKE RELATERT til din prostatakreft. 
Vi er klar over at andre sykdommer som du kan ha i tillegg til din prostatakreft, kan påvirke svarene dine. Hvert 
spørsmål skal besvares ved å sette ett kryss ved det som passer best for deg. Hvis du er usikker på hva du skal 
svare, vennligst svar så godt du kan. 
Utmerket……………………………                            
Meget god …………………………..                       
God……….…………………………                       
Nokså god…………………………..                        
Dårlig………………………………                       
2. Moderate aktiviteter som å flytte et bord, støvsuge, gå en tur eller drive med hagearbeid  
Ja, begrenser meg mye……………….  
Ja, begrenser meg lit……………….         
Nei, begrenser meg ikke i det hele tatt.          
3. Gå opp trappen flere etasjer   
Ja, begrenser meg mye……………….    
Ja, begrenser meg litt ………………..    
Nei, begrenser meg ikke i det hele tatt.    
  Ja                    Nei 
a. Du har utrettet mindre enn du hadde ønsket……  ………    
b. Du har vært hindret i visse typer arbeid eller andre gjøremål   ….   
                             
Ja                    Nei 
a. Du har utrettet mindre enn du hadde ønsket……………………
b. Du har utført arbeidet eller andre gjøremål mindre  
grundig enn vanlig………………………………………………   
 
 
 
Ikke i det hele tatt…………………...           
Litt…………………………………..           
Endel……….………………………..      
Mye……..…………………………..                      
Svært mye..…………………………         
De neste spørsmålene handler om aktiviteter som du kanskje utfører i løpet av en 
vanlig dag. Er din helse slik at den begrenser deg i utførelsen av disse aktivitetene nå? 
Hvis ja, hvor mye?  
4. Har du hatt noen av følgende problemer i ditt arbeid eller i andre av dine daglige 
gjøremål på grunn av din fysiske helse i løpet av DE SISTE 4 UKENE?  
5. I løpet av DE SISTE 4 UKENE har du hatt følelsesmessige problemer som har ført 
til vanskeligheter i ditt arbeid eller i andre av dine daglige gjøremål (f.eks. fordi du har 
følt deg deprimert eller engstelig)? Sett ett kryss på hver linje 
6. I løpet av DE SISTE 4 UKENE, hvor mye har smerter påvirket ditt vanlige arbeid 
(gjelder både arbeid utenfor hjemmet og husarbeid)?  
28. Stort sett, vil du si at din helse de siste 4 ukene er?  
  
 
Hvor ofte i løpet av DE SISTE 4 UKENE?  Sett ett kryss på hver linje 
  Hele      Nesten    Mye av    En del        Litt av         Ikke i 
                                                    tiden      hele        tiden       av tiden     tiden     det hele 
 tiden                                                   tatt   . 
a. Har du følt deg rolig og harmonisk?.             
b. Har du følt deg full av tiltakslyst?                
c. Har du følt deg nedfor og trist?                 
Hele tiden………………….………..       
Nesten hele tiden……………………        
En del av tiden……….……………..        
Litt av tiden……..…………………..   
Ikke i det hele tatt..…………………          
 
 
 
 
 
SPØRSMÅL OM VÆREMÅTER (EPQ-N) 
 
Spørsmålene nedenfor dreier seg om hvordan du vanligvis opptrer, føler og handler. Vennligst kryss av for enten 
Ja eller Nei for hvert spørsmål. Svar hurtig og ikke tenk for lenge over den nøyaktige meningen med hvert 
spørsmål.  
27. Sett ett kryss på hver linje 
 
Ja 
 
Nei 
 
a. Blir dine følelser lett såret?...................................................................    
b. Hender det ofte at du ”går trøtt”?.........................................................   
c. Er du ofte bekymret?............................................................................   
d. Bekymrer du deg for at fryktelige ting kan skje?.................................   
e. Har du ofte følt deg trøtt og giddesløs uten grunn?...............................   
f. Bekymrer du deg lenge etter en pinlig opplevelse?...............................    
7. De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt 
det DE SISTE 4 UKENE. For hvert spørsmål, vennligst velg det svaralternativet som best 
beskriver hvordan du har hatt det.  
8. I løpet av DE SISTE 4 UKENE, hvor mye av tiden har din fysiske helse eller 
følelsesmessige problemer påvirket din sosiale omgang (som det å besøke venner, 
slektninger osv.)?  
  
SPØRSMÅL OM HVORDAN DU FØLER DEG (HADS) 
Her kommer noen spørsmål om hvorledes du føler deg. For hvert spørsmål setter du kryss for ett av de fire 
svarene som best beskriver dine følelser den siste uka. Ikke tenk for lenge på svaret - de spontane svarene er 
best. Sett ett kryss for hvert spørsmål. 
36. Jeg føler meg nervøs og urolig 
 Mesteparten av tiden 
 Mye av tiden 
 Fra tid til annen 
Ikke i det hele tatt
37. Jeg gleder meg fortsatt over  
tingene slik jeg pleide før 
 Avgjort like mye 
 Ikke fullt så mye 
 Bare lite grann 
 Ikke i det hele tatt 
 
38. Jeg har en urofølelse som om  
noe forferdelig vil skje   
    Ja, og noe svært ille 
Ja, ikke så veldig ille
 Litt, bekymrer meg lite 
 Ikke i det hele tatt 
 
39. Jeg kan le og se det morsomme  
i situasjoner 
      Like mye nå som før 
 Ikke like mye nå som før 
 Avgjort ikke som før 
 Ikke i det hele tatt 
40. Jeg har hodet fullt av bekymringer      
 
 Veldig ofte 
 Ganske ofte 
 Av og til 
 En gang i blant 
 
41. Jeg er i godt humør 
 Aldri 
 Noen ganger 
 Ganske ofte 
 For det meste   
42. Jeg kan sitte i fred og ro 
og kjenne meg avslappet 
 Ja, helt klart 
 Vanligvis 
 Ikke så ofte 
 Ikke i det hele tatt       
43. Jeg føler meg som om alt går langsommere  
         Nesten hele tiden 
         Svært ofte 
         Fra tid til annen 
Ikke i det hele tatt
 
44. Jeg føler meg urolig som om 
       jeg har sommerfugler i magen            
         Ikke i det hele tatt 
         Fra tid til annen    
         Ganske ofte 
         Svært ofte 
          
45. Jeg bryr meg ikke lenger  
      om hvordan jeg ser ut 
         Ja, har sluttet å bry meg        
Ikke som jeg burde
         Kan hende ikke nok 
         Bryr meg som før 
 
46. Jeg er rastløs som om  
       jeg stadig må være aktiv 
         Uten tvil svært mye 
         Ganske mye 
         Ikke så veldig mye 
         Ikke i det hele tatt 
 
47. Jeg ser med glede frem  
    til hendelser og ting 
         Like mye som før 
         Heller mindre enn før 
         Avgjort mindre enn før 
         Nesten ikke i det hele tatt       
          
48. Jeg kan plutselig få en 
      følelsen av panikk 
         Uten tvil svært ofte 
         Ganske ofte 
         Ikke så veldig ofte 
         Ikke i det hele tatt 
 
49. Jeg kan glede meg over gode  
      bøker, radio og TV 
         Ofte 
         Fra tid til annen 
         Ikke så ofte 
         Svært sjelden 
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SPØRSMÅL OM ARBEIDSEVNE (WAI)  
Meget god    
Ganske god    
Rimelig god     
Nokså dårlig    
Svært dårlig    
Ikke i arbeid    
 
 
                       
Meget god    
Ganske god    
Rimelig god     
Nokså dårlig    
Svært dårlig    
Ikke i arbeid    
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SPØRSMÅL OM TILFREDSHET 
 
 
Ekstremt utilfreds Utilfreds         Usikker         Tilfreds      Meget tilfreds   
                                
 
   
Ekstremt utilfreds Utilfreds         Usikker         Tilfreds      Meget tilfreds   
                                
    
50. Hvordan vurderer du din arbeidsevne med tanke på de fysiske krav ved ditt 
arbeid? 
51. Hvordan vurderer du din arbeidsevne med tanke på de psykiske krav ved 
ditt arbeid?  
54. Samlet sett, hvor tilfreds er du med informasjonen om og behandlingen av 
din urinlekkasje som du har fått av de ansatte i helsevesenet (leger, sykepleiere, 
uroterapeuter)  
53. Samlet sett, hvor tilfreds er du med informasjonen om og behandlingen av 
din prostatakreft som du har fått av de ansatte i helsevesenet (leger, sykepleiere, 
uroterapeuter, stråleterapeuter)  
52. La oss gå ut fra at arbeidsevnen din på ditt beste ville fått 10 poeng. Hvor 
mange poeng vil du da gi din nåværende arbeidsevne? (0 innebærer at du ikke er i 
stand til å arbeide i det hele tatt. Sett ett kryss under det tallet som best tilsvarer din 
nåværende arbeidsevne. Besvar spørsmålet også om du ikke lenger er i arbeid.) 
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SPØRSMÅL OM OPERASJONEN FOR URINLEKKASJE 
 
Spørsmålene markert med (a) AMS800) ble bare sendt til pasienter med sfinkterprotese og spørsmålene markert 
med (b) AdVance) ble bare sendt til pasientene med slynge.For øvrig var spørsmålene like for alle pasientene. 
 
 
 
                               
Veldig fornøyd      Litt fornøyd         Usikker       Misfornøyd 
         
    
 
 
                         
      Ja      Nei  
   
 
 
                         
 
      Ja    Nei   
 
 
                            
 
 Ja    Nei  
 
 
 
 
                         
       Ja       Nei   
 
 
 
 
Ja   Ja, med forbehold         Usikker             Nei  
           
 
 
 
  
 Ja  Nei  
 
 
 
                       
 
Ja, den er blitt bedre  Nei, ingen innvirkning Ja, den er blitt dårligere 
           
   
 
1. Er du fornøyd med operasjonen for urinlekkasje?  
2. (a) AMS800) Synes du lukkeprotesen er enkel å bruke?  
3. (a) AMS800) Har du noe ubehag i forbindelse med bruk av protesen/pumpen?  
4. Vil du anbefale andre med urinlekkasje en slik operasjon?  
6. Har inngrepet hatt noen innvirkning på seksualfunksjonen din?  
5. Ville du valgt en slik operasjon på nytt i ettertid?  
3. (b) AdVance) Har du hatt smerter pga. operasjonen de siste 4 ukene?  
2. (b) AdVance) Har du hatt problemer med å tømme blæren de siste 4 ukene?  
